Science and Practice 産科婦人科臨床シリーズ 5 悪性腫瘍

出版社: 中山書店
著者:
発行日: 2020-07-30
分野: 臨床医学:外科  >  産婦人科学
ISBN: 9784521747651
電子書籍版: 2020-07-30 (初版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

22,000 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

22,000 円(税込)

商品紹介

子宮,卵巣,卵管,外陰,腟,絨毛―小骨盤腔から発生する婦人科悪性腫瘍の最大の特徴は,生物学的な多様性にある.
多種多様な腫瘍の組織分類・進行期分類・遺伝子解析をふまえた診断・治療方針を主軸に,妊娠中の患者への根治療法から将来妊娠・出産を希望する患者への妊孕性温存療法まで言及し,婦人科腫瘍学の基礎研究に基づく個別化治療を示す.

目次

  • 1章 子宮頸癌
     付表1 子宮頸癌の臨床進行期分類
     分子生物学の進歩
     病理診断法
     画像診断法
     手術療法
     放射線療法
     化学療法
     TOPICS 免疫療法の進歩

    2章 外陰癌
     付表2 外陰癌の手術進行期分類
     発生,組織学的分類,病期分類
     診断と治療

    3章 子宮体癌
     付表3 子宮内膜癌の手術進行期分類
     子宮内膜癌における分子生物学の進歩
     病理診断法
     TOPICS 子宮体癌の特殊組織型
     画像診断法
     手術療法
     内視鏡手術
     妊孕性温存療法としてのホルモン療法
     薬物療法
     放射線治療

    4章 子宮肉腫
     付表4 平滑筋肉腫/子宮内膜間質肉腫の手術進行期分類
     病理学的分類の変化と病態解明
     病理診断法
     画像診断法
     治療法

    5章 卵巣癌
     付表5 卵巣癌・卵管癌・腹膜癌の手術進行期分類
     進行期分類,組織学的分類
     病理診断法
     分子生物学の進歩
     TOPICS 卵 巣悪性腫瘍のゲノム異常
      ―明細胞癌,類内膜癌,顆粒膜細胞腫,成熟嚢胞性奇形腫悪性転化
     手術療法―最新の卵巣癌手術の考え方
     薬物療法
     TOPICS 分子標的治療薬と免疫チェックポイント阻害薬の臨床試験と将来の展望
     TOPICS 腹膜癌・卵管癌の発生・病態・診断・治療
     境界悪性腫瘍の病態理解の進歩

    6章 絨毛性疾患
     付表6 FIGO 2000 staging and risk factor scoring system for gestational
          trophoblastic neoplasia (GTN)
     絨毛性疾患の発生と病理診断
     胞状奇胎・侵入奇胎・絨毛癌の分類・診断法
     胞状奇胎・侵入奇胎・絨毛癌の治療法

    7章 患者への医療的サポート,こころのケア
     若年者のがん-妊孕性温存療法の進歩・妊娠中の婦人科がん治療の進歩
     がん・生殖医療の進歩
     高齢者のがん治療
     緩和医療の進歩,がん随伴症状の緩和
     TOPICS 婦人科がんとサイコオンコロジー
     TOPICS cancer survivor

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 子宮頸癌

P.9 掲載の参考文献
1) zur Hausen H. Papillomavirus and cancer : from basic studies to clinical application. Nat Rev Cancer 2002 ; 2 : 342-50.
2) You J. Papillomavirus interaction with cellular chromatin. Biochim Biophys Acta 2010 ; 1799 : 192-9.
3) Bosch FX, de Sanjose S. Human papillomavirus and cervical cancer : burden and assessment of causality. J Natl Cancer Inst Monogr 2003 ; (31) : 3-13.
4) Ho GY, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998 ; 338 : 423-8.
5) 川名敬ほか. STDは子宮頸がん・外陰がんを増加させているか? 産科と婦人科2003 ; 70 : 1173-9.
6) Inoue M, et al. The evaluation of human papillomavirus DNA testing in primary screening for cervical lesions in a large Japanese population. Int J Gynecol Cancer 2006 ; 16 : 1007-13.
7) Frazer I, Vaccine Development Team. The current status of development of prophylactic vaccines against human papillomavirus infection. Report of a technical meeting. Geneva : WHO ; 16-18 February, 1999.
8) Miura S, et al. Do we need a different strategy for HPV screening and vaccination in East Asia? Int J Cancer 2006 ; 119 : 2713-5.
9) Franco EL, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999 ; 180 : 1415-23.
10) Holowath P, et al. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999 ; 91 : 252-8.
11) Matsumoto K, et al. Japan HPV And Cervical Cancer Study Group. Predicting the progression of cervical precursor lesions by human papillomavirus genotyping : a prospective cohort study. Int J Cancer 2011 ; 128 : 2898-910.
12) Furuta R, et al. Ectopic chromosome around centrosome in metaphase cells as a marker of high-risk human papillomavirus-associated cervical intraepithelial neoplasias. Int J Cancer 2003 ; 106 : 167-71.
13) Mirkovic J, et al. Carcinogenic HPV infection in the cervical squamo-columnar junction. J Pathol 2015 ; 236 : 265-71.
14) Hu Z, et al. Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism. Nat Genet 2015 ; 47 : 158-63.
15) Kukimoto I, et al. Hypermutation in the E2 gene of human papillomavirus type 16 in cervical intraepithelial neoplasia. J Med Virol 2015 ; 87 : 1754-60. doi : 10.1002/jmv.24215.
16) Sato M, et al. Regeneration of cervical reserve cell-like cells from human induced pluripotent stem cells (iPSCs) : a new approach to finding targets for cervical cancer stem cell treatment. Oncotarget 2017 ; 8 : 40935-45.
17) Nishida H, et al. Systemic delivery of siRNA by actively targeted polyion complex micelles for silencing the E6 and E7 human papillomavirus oncogenes. J Control Release 2016 ; 231 : 29-37.
18) Ikeda Y, et al. Safety and efficacy of mucosal immunotherapy using human papillomavirus (HPV) type 16 E7-expressing Lactobacillus-based vaccine for the treatment of high-grade squamous intraepithelial lesion (HSIL) : the study protocol of a randomized placebo-controlled clinical trial (MILACLE study). Jpn J Clin Oncol 2019 ; 49 : 877-80.
P.20 掲載の参考文献
日本産科婦人科学会・日本産婦人科医会編. 産婦人科診療ガイドライン-婦人科外来編 2017. 東京 : 日本産科婦人科学会 ; 2017. p.39-57.
坂本穆彦編. 子宮頸部細胞診運用の実際. 第2版. ベセスダシステム 2014 準拠. 東京 : 医学書院 ; 2017. p.1-22, 193-210.
坂本穆彦編. 細胞診を学ぶ人のために. 第5版. 東京 : 医学書院 ; 2011. p.68-83.
日本婦人科腫瘍学会編. 改訂コルポスコピースタンダードアトラス : 日本婦人科腫瘍学会 2014. 東京 : 中外医学社 ; 2014. p.8-9, 49-52.
日本産科婦人科学会・日本病理学会編. 子宮頸癌取扱い規約 病理編. 第4版. 東京 : 金原出版 ; 2017. p.1-56.
日本産科婦人科学会. 子宮頸癌進行期分類 (FIGO2018) についてのお知らせ. 日産婦誌 2019 ; 71 : 119.
P.26 掲載の参考文献
1) 日本産科婦人科学会・日本病理学会編. 子宮頸癌取扱い規約. 第4版. 東京 : 金原出版 ; 2017.
3) Togashi K, et al. Carcinoma of the cervix : staging with MR imaging. Radiology 1989 ; 171 : 245-51.
4) Hricak H, et al. Carcinoma of the uterus : use of gadopentetate dimeglumine in MR imaging. Radiology 1991 ; 181 : 95-106.
5) 日本医学放射線学会編. 画像診断ガイドライン 2016年版. 東京 : 金原出版 ; 2016.
6) Lee SI, Atri M. 2018 FIGO Staging System for Uterine Cervical Cancer : Enter Cross-sectional Imaging. Radiology 2019 ; 292 : 15-24.
7) Elit L, et al. Follow-up for women after treatment for cervical cancer : a systematic review. Gynecol Oncol 2009 ; 114 : 528-35.
8) Meads C, et al. Evaluating PET-CT in the detection and management of recurrent cervical cancer : systematic reviews of diagnostic accuracy and subjective elicitation. BJOG 2014 ; 121 : 398-407.
9) Liu B, et al. A comprehensive comparison of CT, MRI, positron emission tomography or positron emission tomography/CT, and diffusion weighted imaging-MRI for detecting the lymph nodes metastases in patients with cervical cancer : a meta-analysis based on 67 studies. Gynecol Obstet Invest 2017 ; 82 : 209-22.
10) Kawauchi S, et al. Is lobular endocervical glandular hyperplasia a cancerous precursor of minimal deviation adenocarcinoma? : a comparative molecular-genetic and immunohistochemical study. Am J Surg Pathol 2008 ; 32 : 1807-15.
11) Takatsu A, et al. Preoperative differential diagnosis of minimal deviation adenocarcinoma and lobular endocervical glandular hyperplasia of the uterine cervix : a multicenter study of clinicopathology and magnetic resonance imaging findings. Int J Gynecol Cancer 2011 ; 21 : 1287-96.
12) Song J, et al. Multicystic mucinous adenocarcinoma of the uterine cervix compared with benign multicystic lesions : multiparametric MR features. J Magn Reson Imaging 2018 ; 48 : 1336-43.
P.35 掲載の参考文献
1) 田崎瑛生. 日本における子宮頸癌に対する放射線治療の歴史的展開. J Jpn Soc Ther Radiol Oncol 1999 ; 11 : 157-73.
2) 塚本直樹, Homesley HD. アメリカにおける頸癌手術の動向. 矢嶋聰, 桑原慶紀編. 図説産婦人科 VIEW 30 子宮頸癌の根治手術. 東京 : メジカルビュー社 ; 1998. p.20-5.
3) 三上幹男. 子宮頸癌IIBに対しての広汎子宮全摘術 (RH)はどうあるべきか? 日本臨牀 2018 ; 76 (増刊 2) : 290-5.
4) Machida H, et al. Profile of treatment-related complications in women with clinical stage IB-IIB cervical cancer : a nationwide cohort study in Japan. PLoS One 2019 ; 14 : e0210125.
5) 日本婦人科腫瘍学会編. 子宮頸癌治療ガイドライン 2017年版. 東京 : 金原出版 ; 2017. https://jsgo.or.jp/guideline/keigan2017.html
6) Kobayashi Y. Conization. In : Mikami M, editor. Surgery for Gynecologic Cancer. Comprehensive Gynecology and Obstetrics. Springer ; 2019. p.43-54.
7) 平松祐司. 子宮頸部円錐切除術cervical conization. 櫻木範明担当編集委員. OGS NOW 5 子宮頸癌・外陰癌の手術 理論と実際. 東京 : メジカルビュー社 ; 2011. p.116-25.
8) Mikami M, et al. The use of conization to identify and treat severe lesions among prediagnosed CIN1 and 2 patients in Japan. J Gynecol Oncol 2018 ; 29 : e46.
9) Yamamoto R, et al. Value and limitation of conization as a diagnostic procedure for cervical neoplasm. J Obstet Gynaecol Res 2019 ; 45 : 2419-24.
10) Querleu D, et al. 2017 Update on the Querleu-Morrow Classification of Radical Hysterectomy. Ann Surg Oncol 2017 ; 24 : 3406-12. doi : 10.1245/s10434-017-6031-z. Epub 2017 Aug 7.
11) NCCN Clinical Practice Guidelines in Oncology Cervical Cancer. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf
12) Kato T. Abdominal nerve-sparing radical hysterectomy. In : Mikami M, editor. Surgery for Gynecologic Cancer. Comprehensive Gynecology and Obstetrics. Springer ; 2019. p.89-101.
13) 金内優典. 広汎子宮全摘術 (機能温存手技). 櫻木範明担当編集委員. OGS NOW 5 子宮頸癌・外陰癌の手術 理論と実際. 東京 : メジカルビュー社 ; 2011. p.56-71.
14) NCCN. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf
15) ESGO. https://guidelines.esgo.org/cervical-cancer/guidelines/recommendations/
16) Matsuo K, et al. Predictors for pathological parametrial invasion in clinical stage IIB cervical cancer. Eur J Surg Oncol 2019 ; 45 : 1417-24. doi : 10.1016/j.ejso.2019.02.019. Epub 2019 Feb 18.
17) Matsuo K, et al. Risk stratification models for para-aortic lymph node metastasis and recurrence in stage IB-IIB cervical cancer. J Gynecol Oncol 2018 ; 29 : e11. doi : 10.3802/jgo.2018.29.e11.
18) Matsuo K, et al. Quality and quantity metrics of pelvic lymph node metastasis and risk of para-aortic lymph node metastasis in stage IB-IIB cervical cancer. J Gynecol Oncol 2018 ; 29 : e10. doi : 10.3802/jgo.2018.29.e10.
19) Watanabe T, et al. Quality indicators for cervical cancer care in Japan. J Gynecol Oncol 2018 ; 29 : e83. doi : 10.3802/jgo.2018.29.e83.
20) Matsuo K, et al. Comparison of adjuvant therapy for node-positive clinical stage IB-IIB cervical cancer : systemic chemotherapy versus pelvic irradiation. Int J Cancer 2017 ; 141 : 1042-51.
21) Matoda M, et al. Postoperative chemotherapy for node-positive cervical cancer : results of a multicenter phase II trial (JGOG1067). Gynecol Oncol 2018 ; 149 : 513-9.
22) Mikami M, et al. Impact of institutional accreditation by the Japan Society of Gynecologic Oncology on the treatment and survival of women with cervical cancer. J Gynecol Oncol 2018 ; 29 : e23. doi : 10.3802/jgo.2018.29.e23.
23) Matsuo K, et al. Association of radical hysterectomy surgical volume and survival for early-stage cervical cancer. Obstet Gynecol 2019 ; 133 : 1086-98.
24) Aletti GD, Cliby WA. Time for centralizing patients with ovarian cancer : what are we waiting for? Gynecol Oncol 2016 ; 142 : 209-10.
25) Kobayashi E, et al. Laparoscopic radical hysterectomy. In : Mikami M, editor. Surgery for Gynecologic Cancer. Comprehensive Gynecology and Obstetrics. Springer ; 2019. p.135-49.
26) Mandai M, et al. Robotic surgery for gynecologic cancer. In : Mikami M, editor. Surgery for Gynecologic Cancer. Comprehensive Gynecology and Obstetrics. Springer ; 2019. p.151-62.
27) 安藤正明ほか. 広汎子宮全摘術 (鏡視下). 櫻木範明担当編集委員. OGS NOW 5 子宮頸癌・外陰癌の手術 理論と実際. 東京 : メジカルビュー社 ; 2011. p.72-85.
28) Nezhat CR, et al. Laparoscopic radical hysterectomy with paraaortic and pelvic node dissection. Am J Obstet Gynecol 1992 ; 166 : 864-5.
29) Ramirez PT, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med 2018 ; 379 : 1895-904. doi : 10.1056/NEJMoa1806395. Epub 2018 Oct 31.
30) 三上幹男, 松尾高司. 特集 外科解剖学から解き明かす広汎子宮全摘出術―腹腔鏡下および開腹下の子宮頸癌に対する広汎子宮全摘出術の将来展望. 産婦人科の実際 2018 ; 67 : 1701-11.
31) Yanazume S, Kobayashi H. Radical trachelectomy. In : Mikami M, editor. Surgery for Gynecologic Cancer. Comprehensive Gynecology and Obstetrics. Springer ; 2019. p.163-82.
32) 藤井多久磨ほか. 広汎性子宮頸部摘出術. 櫻木範明担当編集委員. OGS NOW 5 子宮頸癌・外陰癌の手術 理論と実際. 東京 : メジカルビュー社 ; 2011. p.86-93.
33) 斎藤豪ほか. 腟式広汎子宮頸部摘出術. 櫻木範明担当編集委員. OGS NOW 5 子宮頸癌・外陰癌の手術 理論と実際. 東京 : メジカルビュー社 ; 2011. p.94-101.
34) Machida H, et al. Fertility-sparing trachelectomy for early-stage cervical cancer : a proposal of an ideal candidate. Gynecol Oncol 2019 Nov 23. pii : S0090-8258 (19) 31672-5. doi : 10.1016/j.ygyno.2019.11.021. [Epub ahead of print]
35) Niikura H. Sentinel node navigation surgery. In : Mikami M, editor. Surgery for Gynecologic Cancer. Comprehensive Gynecology and Obstetrics. Springer ; 2019. p.237-45.
36) International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer (SENTICOL III). https://clinicaltrials.gov/ct2/show/NCT03386734
P.44 掲載の参考文献
1) 榎本隆之ほか. 婦人科腫瘍委員会報告. 日産婦誌 2019 ; 71 : 854-61.
2) Cervical Cancer (version 4.2019). NCCN Clinical Practice Guidelines in Oncology. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf
3) 日本婦人科腫瘍学会編. 子宮頸癌治療ガイドライン 2017年版, 東京 : 金原出版 ; 2017.
4) Toita T, et al. Prospective multi-institutional study of definitive radiotherapy with high-dose-rate intracavitary brachytherapy in patients with nonbulky (< 4-cm) stage I and II uterine cervical cancer (JAROG0401/JROSG04-2). Int J Radiat Oncol Biol Phys 2012 ; 82 : e49-56.
5) Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer : a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008 ; 26 : 5802-12.
6) Toita T, et al. Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer : results of a Multi-Institutional Phase 2 Study (JGOG1066). Int J Gynecol Cancer 2012 ; 22 : 1420-26.
7) 日本放射線腫瘍学会. 放射線治療計画ガイドライン 2016年版. 東京 : 金原出版 ; 2016.
8) Mundt AJ, et al. Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Int J Radiat Oncol Biol Phys 2003 ; 56 : 1354-60.
9) Ahamad A, et al. Intensity-modulated radiation therapy after hysterectomy : comparison with conventional treatment and sensitivity of the normal-tissue-sparing effect to margin size. Int J Radiat Oncol Biol Phys 2005 ; 62 : 1117-24.
10) Lin AJ, et al. Intensity modulated radiation therapy and image-guided adapted brachytherapy for cervix cancer. Int J Radiat Oncol Biol Phys 2019 ; 103 : 1088-97.
11) International Commission on Radiation Units and Measurement. Dose and volume specification for reporting intracavitary therapy in gynecology (Report 38). Bethesda ICRU ; 1985.
12) 辻野佳世子ほか. 子宮頸癌腔内照射における鎮痛鎮静法についての全国調査. 臨床放射線 2014 ; 59 : 1226-33.
13) Haie-Meder C, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I) : concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 2005 ; 74 : 235-45.
14) Sturdza A, et al. Image guided brachytherapy in locally advanced cervical cancer : improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol 2016 ; 120 : 428-33.
15) Mazeron R, et al. Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer : results from the prospective multicenter EMBRACE study. Radiother Oncol 2016 ; 120 : 412-19.
16) Okazaki S, et al. Dose-volume parameters and local tumor control in cervical cancer treated with central-shielding external-beam radiotherapy and CT-based image-guided brachytherapy. J Radiat Res 2019 ; 60 : 490-500.
P.49 掲載の参考文献
1) Bonomi P, et al. Randomized trial of three cisplatin dose schedules in squamous cell carcinoma of the cervix : a Gynecologic Oncology Group study. J Clin Oncol 1985 ; 3 : 1079-85.
2) Omura GA, et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix : a Gynecologic Oncology Group study. J Clin Oncol 1997 ; 15 : 165-71.
3) Moore DH, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix : a Gynecologic Oncology Group study. J Clin Oncol 2004 ; 22 : 3113-9.
4) Long HJ 3rd, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix : a Gynecologic Oncology Group study. J Clin Oncol 2005 ; 23 : 4626-33.
5) Monk BJ, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma : a Gynecologic Oncology Group study. J Clin Oncol 2009 ; 27 : 4649-55.
6) Kitagawa R, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer : the open label randomized phase III trial JCOG0505. J Clin Oncol 2015 ; 33 : 2129-35.
7) 日本婦人科腫瘍学会編. 子宮頸癌治療ガイドライン 2017年版. 東京 : 金原出版 ; 2017.
8) Kokka F, et al. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer. Cochrane Database Syst Rev 2015 ; (4) : CD010260.
9) Rydzewska L, et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev 2012 ; (12) : CD007406.
10) Kenter G, et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemotadiation for stage 1b2-2b cervical cancer, EORTC55994. J Clin Oncol 2019 ; 37 : 5503.
11) Tattersall MH, et al. A randomized trial of adjuvant chemotherapy after radical hysterectomy in stage 1b-2a cervical cancer patients with pelvic lymphnode metastasis. Gynecol Oncol 1992 ; 46 : 176-81.
12) Curtin JP, et al. Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy : a randomized phase 3 trial. Gynecol Oncol 1996 ; 61 : 3-10.
13) Lahousen M, et al. Chemotherapy versus radiotherapy versus observation for high risk cervical carcinoma after radical hysterectomy : a randomized, prospective, multicenter trial. Gynecol Oncol 1999 ; 73 : 196-201.
14) Matsuo K, et al. Comparison of adjuvant therapy for node-positive clinical stage 1b-2b cervical cancer : systemic chemotherapy versus pelvic irradiation. Int J Cancer 2017 ; 141 : 1042-51.
15) Sato S, et al. Feasibility study of adjuvant chemotherapy using taxane plus carboplatin for high-risk patients with uterine cervical non-squamous cell carcinoma after radical hysterectomy. Int J Gynecol Cancer 2016 ; 26 : 561-7.
16) 刈谷方俊, 藤井信吾. 子宮頸癌発症機構におけるHuman papillomavirus (HPV) の役割と抗HPVワクチン療法の開発. ウイルス 2002 ; 52 : 287-93.
17) Nair P, et al. Increased angiogenesis in the uterine cervix associated with human papillomavirus infection. Pathol Res Pract 1999 ; 195 : 163-9.
18) Lopez-Ocejo O, et al. Oncogenes and tumor angiogenesis : the HPV 16E6 oncoprotein activates the vascular endothelial growth factor gene promoter in a p53 independent manner. Oncogene 2000 ; 19 : 4611-20.
19) Willett CG, et al. Direct evidence that the VEGF specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004 ; 10 : 145-7.
20) Tewari KS, et al. Bevacizumab for advanced cervical cancer : final overall survival and adverse event analysis of a randomized, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 2017 ; 390 : 1654-63.
21) Monk BJ, et al. Phase II trial of bevacizumab in the treatment of persistent of recurrent squamous cell carcinoma of the cervix : a Gynecologic Oncology Group Study. J Clin Oncol 2009 ; 27 : 1069-74.
22) Zighelboim I, et al. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol 2013 ; 130 : 64-8.
23) Symonds RP, et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa) : a randomized, double blind placebo-controlled phase 2 trial. Lancet Oncol 2015 ; 16 : 1515-24.
P.56 掲載の参考文献
1) Chen Z, et al. Elevated expression of programmed death-1 and programmed death ligand-1 negatively regulates immune response against cervical cancer cells. Mediators Inflamm 2016 ; 2016 : 6891482.
2) Meng Y, et al. PD-L1 expression correlates with tumor infiltrating lymphocytes and response to neoadjuvant chemotherapy in cervical cancer. J Cancer 2018 ; 9 : 2938-45.
3) Feng YC, et al. The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance. Cancer Manag Res 2018 ; 10 : 105-13.
4) Ngwa W, et al. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer 2018 ; 18 : 313-22.
5) Cancer Genome Atlas Research Network. Integrated genomic and molecular characterization of cervical cancer. Nature 2017 ; 543 : 378-84.
6) Vora C, et al. Targeted therapy in cervical cancer. ESMO Open 2019 ; 3 : e000462.
7) Borst J, et al. CD4+ T cell help in cancer immunology and immunotherapy. Nat Rev Immunol 2018 ; 18 : 635-47.
8) Basu P, et al. A randomized phase 2 study of ADXS11-001 Listeria monocytogenes-listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical cancer. Int J Gynecol Cancer 2018 ; 28 : 764-72.
9) Liu Y, et al. PD-1/PD-L1 inhibitors in cervical cancer. Front Pharmacol 2019 ; 10 : 65.
10) Chung HC, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer : results from the phase II KEYNOTE-158 study. J Clin Oncol 2019 ; 37 : 1470-8.
11) Marabelle A, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer : results from the phase II KEYNOTE-158 study. J Clin Oncol 2020 ; 38 : 1-10. Epub 2019 Nov 4.

2章 外陰癌

P.70 掲載の参考文献
1) 杉森甫ほか, 婦人科腫瘍委員会編. 本邦における外陰癌の臨床統計調査報告. 日産婦誌 1995 ; 47 : 685-93.
2) 婦人科腫瘍委員会報告 2017年度患者年報. 日産婦誌 2019 ; 71 : 669-724.
3) Wakeham K, et al. HPV status and favourable outcome in vulvar squamous cancer. Int J Cancer 2017 ; 140 : 1134-46.
4) Nitecki R, Feltmate CM. Human papillomavirus and nonhuman papillomavirus pathways to vulvar squamous cell carcinoma : a review. Curr Probl Cancer 2018 ; 42 : 476-85.
5) Ueda Y, et al. Two distinct pathways to development of squamous cell carcinoma of the vulva. J Skin Cancer 2011 ; 2011 : 951250. doi : 10.1155/2011/951250. Epub 2010 Sep 28.
6) van der Linden M, et al. Paget disease of the vulva. Crit Rev Oncol Hematol 2016 ; 101 : 60-74.
7) Udager AM, et al. Gynecologic melanomas : a clinicopathologic and molecular analysis. Gynecol Oncol 2017 ; 147 : 351-7.
8) Kurman RJ, et al, editors. WHO Classification of Tumours of Female Reproductive Organs. 4th ed. WHO ; 2014.
9) 日本婦人科腫瘍学会編. 外陰がん・腟がん治療ガイドライン 2015年版. 東京 : 金原出版 ; 2015.
10) Podratz KC, et al. Carcinoma of the vulva : analysis of treatment and survival. Obstet Gynecol 1983 ; 61 : 63-74.
11) Homesley HD, et al. Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study). Am J Obstet Gynecol 1991 ; 164 : 997-1004.
12) Hopkins MP, et al. Squamous cell carcinoma of the vulva : prognostic factors influencing survival. Gynecol Oncol 1991 ; 43 : 113-7.
13) Origoni M, et al. Prognostic value of pathological patterns of lymph node positivity in squamous cell carcinoma of the vulva stage III and IVA FIGO. Gynecol Oncol 1992 ; 45 : 313-6.
14) Tabbaa ZM, et al. Impact of the new FIGO 2009 staging classification for vulvar cancer on prognosis and stage distribution. Gynecol Oncol 2012 ; 127 : 147-52.
15) 日本皮膚科学会・日本皮膚悪性腫瘍学会. 皮膚悪性腫瘍ガイドライン 第3版 メラノーマ診療ガイドライン 2019. 日皮会誌 2019 ; 129 : 1759-843.
寒河江悟. 臨床進行期分類. 工藤隆一編. 外陰・腟の悪性腫瘍. 新女性医学体系 38 (武谷雄二総編集). 東京 : 中山書店 ; 1998 ; p.73-89.
Amin MB, et al, editors. AJCC Cancer Staging Manual. 8th ed. Springer ; 2017.
P.81 掲載の参考文献
1) 須川佶ほか. 本邦における外陰癌の発症ならびに治療の現況. 日産婦誌 1980 ; 32 : 177-86.
2) 杉森甫, 工藤隆一. 婦人科腫瘍委員会報告 (本邦における外陰癌の臨床統計調査報告). 日産婦誌 1995 : 47 : 685-93.
3) Tanaka Y, et al. Trends in incidence and long-term survival of Japanese women with vulvar cancer : a population-based analysis. Int J Clin Oncol 2019 ; 24 : 1137-42.
4) Nishio S, et al. Changes in the clinicopathological demographics of vulvar cancer in Japan : increasing oldest-old, stage shifting, and decreasing cohort-level survival. J Clin Med 2019 ; 8 (12). pii : E2081. doi : 10.3390/jcm8122081.
5) Saito T, et al. Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer. Int J Clin Oncol 2018 ; 23 : 201-34.
6) Saito T. Management of lymph nodes in the treatment of vulvar cancer. Int J Clin Oncol 2007 ; 12 : 187-91.
7) Van der Zee AG, et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol 2008 ; 26 : 884-9.
8) Te Grootenhuis NC, et al. Sentinel nodes in vulvar cancer : Long-term follow-up of the GROningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I. Gynecol Oncol 2016 ; 140 : 8-14.
9) Oonk MH, et al. Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer : results from GROINSS-V, a multicentre observational study. Lancet Oncol 2010 ; 11 : 646-52.
10) Levenback CF, et al. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva : a gynecologic oncology group study. J Clin Oncol 2012 ; 30 : 3786-91.
日本婦人科腫瘍学会編. 外陰がん・腟がん治療ガイドライン 2015年版. 東京 : 金原出版 ; 2015.
NCCN Clinical Practice Guideline in Oncology, Vulvar Cancer (Squamous Cell Carcinoma). Version 2. 2019. https://www.nccn.org/professionals/physician_gls/pdf/vulvar.pdf
有吉和也, 齋藤俊章. 外陰上皮内腫瘍 (VIN) の治療 : 病変が広範囲に進展している場合. 平松祐司ほか編. 婦人科がん手術 こんなときどうする? がんの根治とQOLの改善をめざして. 東京 : メジカルビュー社 ; 2013. p.8-17.
有吉和也, 齋藤俊章. 外陰癌・パジェット病・悪性黒色腫. 産婦人科の実際 2016 ; 65 : 1-8.
有吉和也, 齋藤俊章. 外陰癌・腟癌の診断法. 産科と婦人科 2015 ; 82 : 258-61.
齋藤俊章, 寺本典弘. 外陰・腟腫瘍. 片渕秀隆, 森谷卓也編. 一冊でわかる婦人科腫瘍・疾患. 東京 : 文光堂 ; 2017. p.128-37.
齋藤俊章, 塚本直樹. 外陰の上皮性悪性腫瘍の手術療法. 工藤隆一編. 外陰・腟の悪性腫瘍. 新女性医学体系 38. 東京 : 中山書店 ; 1998. p.107-29.
齋藤俊章. 広汎外陰切除術. 櫻木範明編. 子宮頸癌・外陰癌の手術OGS NOW No. 5. 東京 : メジカルビュー社 ; 2011. p.126-39.
齋藤俊章. 外陰癌根治手術の基本手技を学ぶ. 産婦人科手術 2013 ; 24 : 9-16.
齋藤俊章. 研修コーナー クリニカルカンファレンス 8 婦人科腫瘍とQOL. 2) 外陰癌の創部ケア. 日産婦誌 2009 ; 61 : N373-7.
有吉和也, 齋藤俊章. 外陰がんに対する縮小手術. 臨床婦人科産科 2017 ; 71 : 357-62.
Saito T. Surgery for vulvar cancer and vaginal cancer. In : Mikami M, editor. Surgery for Gynecologic Cancer. Tokyo : Springer ; 2019. p.416-30.

3章 子宮体癌

P.98 掲載の参考文献
1) Enomoto T, et al. K-ras activation in neoplasms of the human female reproductive tract. Cancer Res 1990 ; 50 : 6139-45.
2) Enomoto T, et al. K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res 1991 ; 51 : 5308-14.
3) Tashiro H, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997 ; 57 : 3935-40.
4) Kanaya T, et al. Association of mismatch repair deficiency with PTEN frameshift mutations in endometrial cancers and the precursors in a Japanese population. Am J Clin Pathol 2005 ; 124 : 89-96.
5) Mutter GL, et al. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 2001 ; 61 : 4311-4.
6) Fukuchi T, et al. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 1998 ; 58 : 3526-8.
7) Enomoto T, et al. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res 1993 ; 53 : 1883-8.
8) Tashiro H, et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997 ; 150 : 177-85.
9) Kanaya T, et al. Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. Oncogene 2003 ; 22 : 2352-60.
10) Schwartz S, et al. Frameshift mutations at mononucleotide repeats in caspase-5 and other target genes in endometrial and gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res 1999 ; 9 : 2995-3002.
11) Vassileva V, et al. Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability. Cancer Res 2002 ; 62 : 4095-9.
12) Cancer Genome Atlas Research Network, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013 ; 497 : 67-73.
13) Talhouk A, et al. Confirmation of ProMisE : a simple, genomics-based clinical classifier for endometrial cancer. Cancer 2017 ; 123 : 802-13.
14) Tanaka M, et al. Evidence of the monoclonal composition of human endometrial epithelial glands and mosaic pattern of clonal distribution in luminal epithelium. Am J Pathol 2003 ; 163 : 295-301.
15) Kato K, et al. Characterization of side-population cells in human normal endometrium. Hum Reprod 2007 ; 22 : 1214-23.
16) Nakamura M, et al. Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer. Hum Pathol 2010 ; 41 : 1516-29.
17) Kyo S, et al. Endometrial cancer stem cell as a potential therapeutic target. Semin Reprod Med 2015 ; 33 : 341-9.
18) Suda K, et al. Clonal expansion and diversification of cancer-associated mutations in endometriosis and normal endometrium. Cell Rep 2018 ; 24 : 1777-89.
19) Kyo S, et al. Stem cells in endometrium and endometrial cancer : accumulating evidence and unresolved questions. Cancer Lett 2011 ; 308 : 123-33.
P.113 掲載の参考文献
1) 榎本隆之. 婦人科腫瘍委員会報告. 2017年度患者年報. 日産婦誌 2019 ; 71 : 669-724.
2) 日本産科婦人科学会・日本病理学会編. 子宮体癌取扱い規約 病理編. 第4版. 東京 : 金原出版 ; 2017.
3) Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983 ; 15 : 10-7.
4) Kurman RJ, et al. Bokhman's dualistic model of endometrial carcinoma. Revisited. Gynecol Oncol 2013 ; 129 : 271-2.
5) Zaino R, et al. Epithelial tumours and precursors. In : Kurman RJ, et al, editors. WHO Classification of Tumours of Female Reproductive Organs. Lyon : International Agency for Recearch on Cancer ; 2014. p.125-35.
6) Zaino RJ, et al. The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A Gynecologic Oncology Group study. Cancer 1995 ; 75 : 81-6.
7) Dockerty MB, et al. Leventhal syndrome : analysis of 43 cases with special reference to association with endometrial carcinoma. Am J Obstet Gynecol 1957 ; 73 : 161-73.
8) Bhaskaran K, et al. Body-mass index and risk of 22 specific cancers : a population-based cohort study of 5.24 million UK adults. Lancet 2014 ; 384 : 755-65.
9) Kaaks R, et al. Obesity, endogenous hormones, and endometrial cancer risk : a synthetic review. Cancer Epidemiol Biomarkers Prev 2002 ; 11 : 1531-43.
10) Lax SF, et al. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Pathol 1997 ; 81 : 228-32.
11) Erdenebaatar C, et al. Serum prolactin contributes to enhancing prolactin receptor and pJAK2 in type I endometrial cancer cells in young women without insulin resistance. Int J Gynecol Pathol 2019 ; 38 : 318-25.
12) Hernandez AV, et al. Insulin resistance and endometrial cancer risk : a systematic review and meta-analysis. Eur J Cancer 2015 ; 51 : 2747-58.
13) Tashiro H, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997 ; 57 : 3935-40.
14) The Cancer Genome Atlas. Integrated genomic characterization of endometrial carcinoma. Nature 2013 ; 497 : 67-73.
15) Katabuchi H, et al. Mutations in DNA mismatch repair genes are not responsible for microsatellite instability in most sporadic endometrial carcinomas. Cancer Res 1995 ; 55 : 5556-60.
16) Esteller M, et al. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 1998 ; 17 : 2413-7.
17) Esteller M, et al. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol 1999 ; 155 : 1767-72.
18) Kanaya T, et al. Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. Oncogene 2003 ; 22 : 2352-60.
19) Le DT, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017 ; 357 : 409-13.
20) 山本直ほか. 婦人科がんにおけるMSI-H Cancerの診断と治療. 癌と化学療法 2018 ; 45 : 1577-81.
22) Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015 ; 372 : 2509-20.
23) van Gool IC, et al. POLE proofreading mutations elicit an antitumor immune response in endometrial cancer. Clin Cancer Res 2015 ; 21 : 3347-55.
24) Stasenko M, et al. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. Gynecol Oncol 2020 ; 156 : 194-202.
25) Tashiro H, et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997 ; 150 : 177-85.
26) Tashiro H, et al. Microsatellite instability is uncommon in uterine serous carcinoma. Am J Pathol 1997 ; 150 : 75-9.
27) DeLair DF, et al. The genetic landscape of endometrial clear cell carcinomas. J Pathol 2017 ; 243 : 230-41.
28) Hecht JL, et al. Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis. Mod Pathol 2005 ; 18 : 324-30.
29) Pavlakis K, et al. MELF invasion in endometrial cancer as a risk factor for lymph node metastasis. Histopathology 2011 ; 58 : 966-73.
30) Euscher E, et al. The pattern of myometrial invasion as a predictor of lymph node metastasis or extrauterine disease in low-grade endometrial carcinoma. Am J Surg Pathol 2013 ; 37 : 1728-36.
31) Segura SE, et al. Clinicopathologic association and prognostic value of MELF pattern in invasive endocervical adenocarcinoma (ECA) as classified by IECC. Int J Gynecol Pathol 2019 Sep 11. [Epub ahead of print]
32) Stelloo E, et al. Practical guidance for mismatch repair-deficiency testing in endometrial cancer. Ann Oncol 2017 ; 28 : 96-102.
33) Jackson CL, et al. Endometrial adenocarcinomas with significant mucinous differentiation : a characterization of intratumoral heterogeneity of KRAS mutations in mucinous and endometrioid histologic components. Int J Gynecol Cancer 2018 ; 28 : 241-7.
34) Zannoni GF, et al. Clear cell carcinoma of the endometrium : an immunohistochemical and molecular analysis of 45 cases. Hum Pathol 2019 ; 92 : 10-7.
35) Zhang ZM, et al. The clinicopathologic significance of the loss of BAF250a (ARID1A) expression in endometrial carcinoma. Int J Gynecol Cancer 2014 ; 24 : 534-40.
36) 片渕秀隆, 田代浩徳. 子宮内膜組織診. 日産婦誌 2007 ; 59 : N69-70.
37) Motohara K, et al. Endometrioid adenocarcinoma arising in adenomyosis : elucidation by periodic magnetic resonance imaging evaluations. Int J Clin Oncol 2008 ; 13 : 266-70.
38) Westin SN, et al. Carcinoma of the lower uterine segment : a newly described association with Lynch syndrome. J Clin Oncol 2008 ; 26 : 5965-71.
39) 日本病理学会編. ゲノム研究用・診療用病理検体取扱い規定. 東京 : 羊土社 ; 2019.
P.118 掲載の参考文献
1) Yamagami W, et al. Clinical statistics of gynecologic cancers in Japan. J Gynecol Oncol 2017 ; 28 : e32.
2) Nagase S, et al. 2017 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology. Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology : annual patients report for 2015 and annual treatment report for 2010. J Obstet Gynaecol Res 2019 ; 45 : 289-98.
3) del Carmen MG, et al. Uterine papillary serous cancer : a review of the literature. Gynecol Oncol 2012 ; 127 : 651-61.
4) Saule C, et al. Risk of serous endometrial carcinoma in women with pathogenic BRCA1/2 variant after risk-reducing salpingo-oophorectomy. J Natl Cancer Inst 2018 ; 110 (2).
5) Cancer Genome Atlas Research Network, Kandoth C, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013 ; 497 : 67-73.
6) Fader AN, et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. J Clin Oncol 2018 ; 36 : 2044-51.
P.124 掲載の参考文献
1) Nougaret S, et al. Endometrial cancer : combined MR volumetry and diffusion-weighted imaging for assessment of myometrial and lymphovascular invasion and tumor grade. Radiology 2015 ; 276 : 797-808.
日本婦人科腫瘍学会. 子宮体がん治療ガイドライン 2018年版. 東京 : 金原出版 ; 2018. p.91-3, 137-9.
日本産科婦人科学会・日本病理学会. 子宮体癌取扱い規約 病理編. 第4版. 東京 : 金原出版 ; 2017. p.9-12.
今岡いずみほか. 婦人科MRI アトラス. 第2版. 東京 : 秀潤社 ; 2019. p.56-70.
松村謙臣ほか企画. 産婦人科診療decision makingのためのMRI・CT. 産婦人科の実際 2019 ; 68 (臨時増刊号) : 699-704.
田中優美子. 産婦人科の画像診断. 東京 : 金原出版 ; 2014. p.167-207.
P.130 掲載の参考文献
1) Lee B, et al. Influence of positive peritoneal cytology on prognostic factors and survival in early-stage endometrial cancer : a systematic review and meta-analysis. Jpn J Clin Oncol 2016 ; 46 : 711-7.
2) Seagle BL, et al. Prognosis and treatment of positive peritoneal cytology in early endometrial cancer : matched cohort analyses from the National Cancer Database. Am J Obstet Gynecol 2018 ; 218 : 329.e1-329.e15.
3) Carey MS, et al. Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium. Gynecol Oncol 1995 ; 57 : 138-44.
4) Signorelli M, et al. Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer : results from the ILIADE randomized study. Ann Surg Oncol 2009 ; 16 : 3431-41.
5) Mariani A, et al. Role of wide/radical hysterectomy and pelvic lymph node dissection in endometrial cancer with cervical involvement. Gynecol Oncol 2001 ; 83 : 72-80.
6) Liu T, et al. Impact of radical hysterectomy versus simple hysterectomy on survival of patients with stage 2 endometrial cancer : a meta-analysis. Ann Surg Oncol 2019 ; 26 : 2933-42.
7) Creasman WT, et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987 ; 60 (8 Suppl) : 2035-41.
8) ASTEC study group, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial) : a randomised study. Lancet 2009 ; 373 : 125-36.
9) Frost JA, et al. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev 2017 ; 10 : CD007585.
10) Mariani A, et al. Prospective assessment of lymphatic dissemination in endometrial cancer : a paradigm shift in surgical staging. Gynecol Oncol 2008 ; 109 : 11-8.
11) Todo Y, et al. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study) : a retrospective cohort analysis. Lancet 2010 ; 375 : 1165-72.
12) Ballester M, et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer : a prospective multicentre study (SENTI-ENDO). Lancet Oncol 2011 ; 12 : 469-76.
13) Rossi EC, et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial) : a multicentre, prospective, cohort study. Lancet Oncol 2017 ; 18 : 384-92.
14) Togami S, et al. Prospective study of sentinel lymph node mapping for endometrial cancer. Int J Gynaecol Obstet 2018 ; 143 : 313-8.
15) Persson J, et al. Pelvic sentinel lymph node detection in High-Risk Endometrial Cancer (SHREC-trial) : the final step towards a paradigm shift in surgical staging. Eur J Cancer 2019 ; 116 : 77-85.
P.139 掲載の参考文献
1) 日本産科婦人科学会婦人科腫瘍委員会報告. 2015年度患者年報. 日産婦誌 2017 ; 69 : 1171-261.
2) Childers JM, Surwit EA. Combined laparoscopic and vaginal surgery for the management of two cases of stage I endometrial cancer. Gynecol Oncol 1992 ; 45 : 46-51.
3) Tozzi R, et al. Laparoscopy versus laparotomy in endometrial cancer : first analysis of survival of a randomized prospective study. J Minim Invasive Gynecol 2005 ; 12 : 130-6.
4) Malzoni M, et al. Total laparoscopic hysterectomy versus abdominal hysterectomy with lymphadenectomy for early-stage endometrial cancer : a prospective randomized study. Gynecol Oncol 2009 ; 112 : 126-33.
5) Zullo F, et al. Laparoscopic surgery vs laparotomy for early stage endometrial cancer : long-term data of a randomized controlled trial. Am J Obstet Gynecol 2009 ; 200 : 296 e1-9.
6) Walker JL, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer : Gynecologic Oncology Group Study LAP2. J Clin Oncol 2009 ; 27 : 5331-6.
7) Janda M, et al. Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE) : a randomised trial. Lancet Oncol 2010 ; 11 : 772-80.
8) Mourits MJ, et al. Safety of laparoscopy versus laparotomy in early-stage endometrial cancer : a randomised trial. Lancet Oncol 2010 ; 11 : 763-71.
9) Fram KM. Laparoscopically assisted vaginal hysterectomy versus abdominal hysterectomy in stage I endometrial cancer. Int J Gynecol Cancer 2002 ; 12 : 57-61.
10) Zorlu CG, et al. Laparoscopy or laparotomy for the management of endometrial cancer. JSLS 2005 ; 9 : 442-6.
11) Kluivers KB, et al. Total laparoscopic hysterectomy versus total abdominal hysterectomy with bilateral salpingo-oophorectomy for endometrial carcinoma : a randomised controlled trial with 5-year follow-up. Gynecol Surg 2011 ; 8 : 427-34.
12) He H, et al. Laparoscopic treatment of endometrial cancer : systematic review. J Minim Invasive Gynecol 2013 ; 20 : 413-23.
13) Walker JL, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer : Gynecologic Oncology Group LAP2 Study. J Clin Oncol 2012 ; 30 : 695-700.
14) Wright JD, et al. Comparative effectiveness of minimally invasive hysterectomy for endometrial cancer. J Clin Oncol 2016 ; 34 : 1087-96.
15) Terai Y, et al. Total laparoscopic modified radical hysterectomy with lymphadenectomy for endometrial cancer compared with laparotomy. J Obstet Gynaecol Res 2014 ; 40 : 570-5.
16) 日本婦人科腫瘍学会編. 子宮体がん治療ガイドライン 2018年版. 東京 : 金原出版 ; 2018.
17) 日本産科婦人科内視鏡学会編. 産婦人科内視鏡手術ガイドライン 2019年版. 東京 : 金原出版, 2019.
18) Uterine Neoplasms (Version 5, 2019) NCCN Clinical Practice Guideleines in Oncology. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf
19) Todo Y, et al. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study) : a retrospective cohort analysis. Lancet 2010 ; 375 : 1165-72.
20) Pakish J, et al. A comparison of extraperitoneal versus transperitoneal laparoscopic para-aortic lymphadenectomy for staging of endometrial carcinoma. Gynecol Oncol 2014 ; 132 : 366-71.
21) Tanaka T, et al. Comparison between laparoscopy and laparotomy in systematic para-aortic lymphadenectomy for patients with endometrial cancer : a retrospective multicenter study. J Gynecol Surg 2017 ; 33 : 105-10.
22) Bouwman F, et al. The impact of BMI on surgical complications and outcomes in endometrial cancer surgey : an institutional study and systematic review of the literature. Gynecol Oncol 2015 ; 139 : 369-76.
23) Uccella S, et al. Impact of obesity on surgical treatment for endometrial cancer : a multicenter study comparing laparoscopy vs open surgery, with propensity-matched analysis. J Minim Invasive Gynecol 2016 ; 23 : 53-61.
24) Park DA, et al. Comparative safety and effectiveness of robot-assisted laparoscopic hysterectomy versus conventional laparoscopy and laparotomy for endometrial cancer. Eur J Surg Oncol 2016 ; 42 : 1303-14.
P.146 掲載の参考文献
1) Zivanovic O, et al. A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer. Gynecol Oncol 2009 ; 115 : 504-9.
2) 榎本隆之. 日本産科婦人科学会婦人科腫瘍委員会報告. 日産婦誌 2019 ; 71 : 854-61.
3) 小西郁生. 日本産科婦人科学会婦人科腫瘍委員会報告. 日産婦誌 2009 ; 61 : 913-97.
4) Banno K, et al. Progestin therapy for endometrial cancer : the potential of fourth-generation progestin (review). Int J Oncol 2012 ; 40 : 1755-62.
5) Shimizu Y, et al. Dienogest, a synthetic progestin, inhibits the proliferation of immortalized human endometrial epithelial cells with suppression of cyclin D1 gene expression. Mol Hum Reprod 2009 ; 15 : 693-701.
6) National Comprehensive Cancer Network. Uterine Neoplasm. Version 4. 2019. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf. Accessed 16 Dec 2019.
7) Colombo N, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer : diagnosis, treatment and follow-up. Ann Oncol 2016 ; 27 : 16-41.
8) Wei J, et al. Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia : a meta-analysis and systematic review. Medicine (Baltimore) 2017 ; 96 : e8034.
9) Fan Z, et al. Fertility-preserving treatment in young women with grade 1 presumed stage IA endometrial adenocarcinoma : a meta-analysis. Int J Gynecol Cancer 2018 ; 28 : 385-93.
10) Kaku T, et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women : central pathologic review and treatment outcome. Cancer Lett 2001 ; 167 : 39-48.
11) Niwa K, et al. Outcome of fertility-preserving treatment in young women with endometrial carcinomas. BJOG 2005 ; 112 : 317-20.
12) Yahata T, et al. Long-term conservative therapy for endometrial adenocarcinoma in young women. Hum Reprod 2006 ; 21 : 1070-5.
13) Ushijima K, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007 ; 25 : 2798-803.
14) Yamazawa K, et al. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod 2007 ; 22 : 1953-8.
15) Minaguchi T, et al. Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium. Cancer Lett 2007 ; 248 : 112-22.
16) Yu M, et al. Fertility-preserving treatment in young women with well-differentiated endometrial carcinoma and severe atypical hyperplasia of endometrium. Fertil Steril 2009 ; 92 : 2122-4.
17) Fujiwara H, et al. Fertility-sparing treatment using medroxyprogesterone acetate for endometrial carcinoma. Oncol Lett 2012 ; 3 : 1002-6.
18) Ohyagi-Hara C, et al. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia : our experience and a review of the literature. Arch Gynecol Obstet 2015 ; 291 : 151-7.
19) Pal N, et al. Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device. Obstet Gynecol 2018 ; 131 : 109-16.
20) Leone Roberti Maggiore U, et al. Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer : a retrospective study. J Gynecol Oncol 2019 ; 30 : e57.
21) Kim MK, et al. Six months response rate of combined oral medroxyprogesterone/levonorgestrel-intrauterine system for early-stage endometrial cancer in young women : a Korean Gynecologic-Oncology Group Study. J Gynecol Oncol 2019 ; 30 : e47.
22) Falcone F, et al. Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer. J Gynecol Oncol 2017 ; 28 : e2.
23) Yang B, et al. Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer. Gynecol Oncol 2019 ; 153 : 55-62.
26) Mu N, et al. Insulin resistance : a significant risk factor of endometrial cancer. Gynecol Oncol 2012 ; 125 : 751-7.
27) Mitsuhashi A, et al. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Ann Oncol 2016 ; 27 : 262-6.
28) Mitsuhashi A, et al. Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients. J Gynecol Oncol 2019 ; 30 : e90.
29) Yamagami W, et al. Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility? J Gynecol Oncol 2018 ; 29 : e21.
30) Stegeman BH, et al. Different combined oral contraceptives and the risk of venous thrombosis : systematic review and network meta-analysis. BMJ 2013 ; 347 : f5298.
31) Lidegaard O, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012 ; 366 : 2257-66.
32) Tchaikovski SN, et al. Mechanisms of estrogen-induced venous thromboembolism. Thromb Res 2010 ; 126 : 5-11.
33) Bergendal A, et al. Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. Obstet Gynecol 2014 ; 124 : 600-9.
34) Tepper NK, et al. Progestin-only contraception and thromboembolism : a systematic review. Contraception 2016 ; 94 : 678-700.
35) Minig L, et al. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women. Ann Oncol 2011 ; 22 : 643-9.
P.156 掲載の参考文献
1) Thigpen JT, et al. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma : a Gynecologic Oncology Group Study. Gynecol Oncol 1989 ; 33 : 68-70.
2) Burke TW, et al. Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecol Oncol 1993 ; 51 : 397-400.
3) van Wijk FH, et al ; European Organization for Research and Treatment of Cancer. Gynaecological Cancer Group. Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group. Eur J Cancer 2003 ; 39 : 78-85.
4) Thigpen JT, et al. Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma : a Gynecologic Oncology Group study. Cancer Treat Rep 1979 ; 63 : 21-7.
5) Calero F, et al. Epirubicin in advanced endometrial adenocarcinoma : a phase II study of the Grupo Ginecologico Espanol para el Tratamiento Oncologico (GGETO). Eur J Cancer 1991 ; 27 : 864-6.
6) Ball HG, et al. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium : a Gynecologic Oncology Group study. Gynecol Oncol 1996 ; 62 : 278-81.
7) Katsumata N, et al. Phase II trial of docetaxel in advanced or metastatic endometrial cancer : a Japanese Cooperative Study. Br J Cancer 2005 ; 93 : 999-1004.
8) Gunthert AR, et al ; Arbeitsgemeinschaft Gynaekologische Onkologie. Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer : AGO Uterus-4. Gynecol Oncol 2007 ; 104 : 86-90.
9) Thigpen JT, et al. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma : a Gynecologic Oncology Group study. J Clin Oncol 1994 ; 12 : 1408-14.
10) Thigpen JT, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma : a gynecologic oncology group study. J Clin Oncol 2004 ; 22 : 3902-8.
11) van Wijk FH, et al ; European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma : definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 2003 ; 14 : 441-8.
12) Fleming GF, et al. Phase III randomized trial of doxorubicin+cisplatin versus doxorubicin+24-h paclitaxel+filgrastim in endometrial carcinoma : a Gynecologic Oncology Group study. Ann Oncol 2004 ; 15 : 1173-8.
13) Fleming GF, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma : a Gynecologic Oncology Group Study. J Clin Oncol 2004 ; 22 : 2159-66.
14) Miller D, et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma : a Gynecologic Oncology Group study. Gynecologic Oncology 2012 ; 125 : 771.
15) Nomura H, et al. Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma : a Japanese Gynecologic Oncology Group study (JGOG2041). Ann Oncol 2011 ; 22 : 636-42.
16) Matei D, et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med 2019 ; 380 : 2317-26.
17) Randall ME, et al ; Gynecologic Oncology Group Study. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma : a Gynecologic Oncology Group Study. J Clin Oncol 2006 ; 24 : 36-44.
18) Homesley HD, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel : a Gynecologic Oncology Group study. Gynecol Oncol 2009 ; 112 : 543-52.
19) Susumu N, et al ; Japanese Gynecologic Oncology Group. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer : a Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008 ; 108 : 226-33.
20) Maggi R, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma : results of a randomised trial. Br J Cancer 2006 ; 95 : 266-71.
21) Nomura H, et al ; Japanese Gynecologic Oncology Group. Effect of taxane plus platinum regimens vs doxorubicin plus cisplatin as adjuvant chemotherapy for endometrial cancer at a high risk of progression : a randomized clinical trial. JAMA Oncol 2019 ; 5 : 833-40.
22) Randall ME, et al. Phase III trial : adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early stage endometrial cancer. J Clin Oncol 2019 ; 37 : 1810-8.
23) Eto T, et al. Status of treatment for the overall population of patients with stage IVb endometrial cancer, and evaluation of the role of preoperative chemotherapy : a retrospective multi-institutional study of 426 patients in Japan. Gynecol Oncol 2013 ; 131 : 574-80.
24) Vandenput I, et al. Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV) : a new preferred treatment. Br J Cancer 2009 ; 101 : 244-9.
25) Martin-Hirsch PP, et al. Adjuvant progestagens for endometrial cancer. Cochrane Database Syst Rev 2011 ; (6) : CD001040.
27) Lentz SS, et al. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma : a Gynecologic Oncology Group Study. J Clin Oncol 1996 ; 14 : 357-61.
28) Marabelle A, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer : results from the Phase II KEYNOTE-158 Study. J Clin Oncol 2019 Nov 4 : JCO1902105.
29) Antill YC, et al. Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status : the phase II PHAEDRA trial (ANZGOG1601). J Clin Oncol 2019 ; 37 : 5501.
30) Konstantinopoulos PA, et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol 2019 ; 37 : 2786-94.
31) Le DT, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer : an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2019 ; 20 : 711-8.
32) Makker V, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer : an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2019 ; 20 : 711-8.
33) Aghajanian C, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer : a Gynecologic Oncology Group study. J Clin Oncol 2011 ; 29 : 2259-65.
34) Aghajanian C, et al. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol 2018 ; 150 : 274-81.
35) Lorusso D, et al. Carboplatin-paclitaxel compared to carboplatin-paclitaxel-bevacizumab in advanced or recurrent endometrial cancer : MITO END-2-a randomized phase II trial. Gynecol Oncol 2019 ; 155 : 406-12.
36) Tsoref D, et al. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol 2014 ; 135 : 184-9.
37) Colombo N, et al. Ridaforolimus as a single agent in advanced endometrial cancer : results of a single-arm, phase 2 trial. Br J Cancer 2013 ; 108 : 1021-6.
38) Oza AM, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer : a trial of the NCIC Clinical Trials Group. J Clin Oncol 2011 ; 29 : 3278-85.
39) Slivovitz BM, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 2010 ; 116 : 5415-9.
40) Matulonis U, et al. Phase II study of the PI3K inhibitor pilaralisib (SAR245408 ; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol 2015 ; 136 : 246-53.
41) Slomovitz BM, et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 2015 ; 33 : 930-6.
42) Slomovitz BM, et al. GOG 3007, a randomized phase II (RP2) trial of everolimus and letrozole (EL) or hormonal therapy (medroxyprogesterone acetate/tamoxifen, PT) in women with advanced, persistent or recurrent endometrial carcinoma (EC) : A GOG Foundation study. Gynecol Oncol 2018 ; 149 Suppl 1 : 2.
43) Fleming GF, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma : a Gynecologic Oncology Group study. Gynecol Oncol 2010 ; 116 : 15-20.
44) Leslie KK, et al. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol 2012 ; 127 : 345-50.
45) Fader AN, et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. J Clin Oncol 2018 ; 36 : 2044-51.
46) 日本婦人科腫瘍学会編. 子宮体がん治療ガイドライン 2018年版. 東京 : 金原出版 ; 2018.
47) National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Uterine Neoplasm Ver. 3.2019 [Cited 1st Dec 2019]. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf
48) Colombo N, et al, on behalf of the ESMO Guidelines Committee. eUpdate Endometrial cancer algorithms [Cited 1st Dec 2019]. https://www.esmo.org/Guidelines/Gynaecological-Cancers/ESMOESGO-ESTRO-Consensus-Conference-on-Endometrial-Cancer/eUpdate-Algorithms
P.164 掲載の参考文献
1) Cervical Cancer Guideline (Version 5.2019). NCCN Clinical Practice Guidelines in Oncology. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf
2) Shigeta S, et al. Assessing the effect of guideline introduction on clinical practice and outcome in patients with endometrial cancer in Japan : a project of the Japan Society of Gynecologic Oncology (JSGO) guideline evaluation committee. J Gynecol Oncol 2017 ; 28 : e76.
3) Colombo N, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer : diagnosis, treatment and follow-up. Ann Oncol 2016 ; 27 : 16-41.
4) 日本婦人科腫瘍学会編. 子宮体がん治療ガイドライン 2018年版. 東京 : 金原出版 ; 2018.
5) Klopp AH, et al. Patient-reported toxicity during pelvic intensity-modulated radiation therapy :NRG Oncology-RTOG 1203. J Clin Oncol 2018 ; 36 : 2538-44.
6) 宇野隆. 腟・腟断端腔内照射. 〔2〕子宮体癌. 日本放射線腫瘍学会小線源治療部会編. 小線源治療部会ガイドラインに基づく密封小線源治療診療・物理QAマニュアル. 東京 : 金原出版 ; 2013. p.102-5.
7) Nag S, et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the endometrium. Int J Radiat Oncol Biol Phys 2000 ; 48 : 779-90.
8) van der Steen-Banasik E, et al. Systemic review : radiation therapy alone in medical non-operable endometrial carcinoma. Eur J Cancer 2016 ; 65 : 172-81.
9) Schwarz JK, et al. Consensus statement for brachytherapy for the treatment of medically inoperable endometrial cancer. Brachytherapy 2015 ; 14 : 587-99.
10) Gill BS, et al. Image-based three-dimensional conformal brachytherapy for medically inoperable endometrial carcinoma. Brachytherapy 2014 ; 13 : 542-7.
11) Ohkubo Y, et al. Dose volume analysis of radiotherapy for inoperable patients with stage I-II endometrial carcinoma. J Radiat Res 2011 ; 52 : 666-73.
12) Kamrava M, et al. American Brachytherapy Society recurrent carcinoma of the endometrium task force patterns of care and review of the literature. Brachytherapy 2017 ; 16 : 1129-43.
13) Lee LJ, et al. Clinical outcomes following 3D image-guided brachytherapy for vaginal recurrence of endometrial cancer. Gynecol Oncol 2013 ; 131 : 586-92.
14) Ho JC, et al. Management of nodal recurrences of endometrial cancer with IMRT. Gynecol Oncol 2015 ; 139 : 40-6.
15) Laliscia C, et al. Clinical outcomes of stereotactic body radiotherapy in oligometastatic gynecological cancer. Int J Gynecol Cancer 2017 ; 27 : 396-402.
16) 日本放射線腫瘍学会編. 緩和. 放射線治療計画ガイドライン 2016年版. 東京 : 金原出版 ; 2016. p.355-69.

4章 子宮肉腫

P.170 掲載の参考文献
1) Cherniack AD, et al. Integrated molecular characterization of uterine carcinosarcoma. Cancer Cell 2017 ; 31 : 411-23.
2) Cancer Genome Atlas Research Network. Electronic address : elizabeth.demicco@sinaihealthsystem.ca ; Cancer Genome Atlas Research Network. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell 2017 ; 171 : 950-65. e28.
3) Hoang L, et al. Endometrial stromal sarcomas and related neoplasms : new developments and diagnostic considerations. Pathology 2018 ; 50 : 162-77.
P.178 掲載の参考文献
1) Mittal KR, et al. Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyoma-like areas. Mod Pathol 2009 ; 22 : 1303-11.
2) Yanai H, et al. Uterine leiomyosarcoma arising in leiomyoma : clinicopathological study of four cases and literature review. Pathol Int 2010 ; 60 : 506-9.
3) Bell SW, et al. Problematic uterine smooth muscle neoplasms : a clinicopathologic study of 213 cases. Am J Surg Pathol 1994 ; 18 : 535-58.
4) Veras E, et al. "Low-grade leiomyosarcoma" and late-recurring smooth muscle tumors of the uterus : a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas. Am J Surg Pathol 2011 ; 35 : 1626-37.
5) Oliva E, et al. An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus : a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. Am J Surg Pathol 2002 ; 26 : 403-12.
6) McCluggage WG, et al. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histopathology 2001 ; 39 : 273-8.
7) Busca A, et al. IFITM1 outperforms CD10 in differentiating low-grade endometrial stromal sarcomas from smooth muscle neoplasms of the uterus. Int J Gynecol Pathol 2018 ; 37 : 372-8.
8) Koontz JI, et al. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad Sci USA 2001 22 ; 98 : 6348-53.
9) Lee CH, et al. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas : a histologically high-grade and clinically aggressive tumor. Am J Surg Pathol 2012 ; 36 : 641-53.
10) Lewis N, et al. ZC3H7B-BCOR high-grade endometrial stromal sarcomas : a report of 17 cases of a newly defined entity. Mod Pathol 2018 ; 31 : 674-84.
11) Marino-Enriquez A, et al. BCOR internal tandem duplication in high-grade uterine sarcomas. Am J Surg Pathol 2018 ; 42 : 335-41.
12) Kolin DL, et al. SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus) : a clinicopathologic entity distinct from undifferentiated carcinoma. Mod Pathol 2018 ; 31 : 1442-56.
13) Goebel EA, et al. Uterine tumor resembling ovarian sex cord tumor (UTROSCT) : a morphologic and molecular study of 26 cases confirms recurrent NCOA1-3 rearrangement. Am J Surg Pathol 2020 ; 44 : 30-42.
14) Bennett JA, et al. Uterine PEComas : a morphologic, immunohistochemical, and molecular analysis of 32 tumors. Am J Surg Pathol 2018 ; 42 : 1370-83.
15) Mills AM, et al. Endocervical fibroblastic malignant peripheral nerve sheath tumor (neurofibrosarcoma) : report of a novel entity possibly related to endocervical CD34 fibrocytes. Am J Surg Pathol 2011 ; 35 : 404-12.
16) Chiang S, et al. NTRK fusions define a novel uterine sarcoma subtype with features of fibrosarcoma. Am J Surg Pathol 2018 ; 42 : 791-8.
17) Croce S, et al. Uterine and vaginal sarcomas resembling fibrosarcoma : a clinicopathological and molecular analysis of 13 cases showing common NTRK-rearrangements and the description of a COL1A1-PDGFB fusion novel to uterine neoplasms. Mod Pathol 2019 ; 32 : 1008-22.
P.183 掲載の参考文献
1) Wui-Jin Koh, et al. NCCN Clinical Practice Guidelines in Oncology. Uterine Neoplasms. 2017 (Version 1. 2018).
2) Zaloudek C, Hendrickson MR. Mesenchymal tumors of the uterus. In : Kurman RJ, et al, eds. Blaustein's Pathology of the Female Genital Tract. 5th ed. New York : Springer-Verlag ; 2002. p.561-616.
3) Kurman RJ, et al. 5. Tumours of the uterine corpus. In : Kuramn RJ, et al, eds. WHO classification of Tumours of Female Reproductive Organas. 4th ed. IARC ; 2014. p.121-54.
4) Sahdev A, et al. MR imaging of uterine sarcomas. AJR Am J Roentgenol 2001 ; 177 : 1307-11.
5) Tanaka YO, et al. Smooth muscle tumors of uncertain malignant potential and leiomyosarcomas of the uterus : MR findings. J Magn Reson Imaging 2004 ; 20 : 998-1007.
6) Schwartz LB, et al. Does pelvic magnetic resonance imaging differentiate among the histologic subtypes of uterine leiomyomata? Fertil Steril 1998 ; 70 : 580-7.
7) Thomassin-Naggara I, et al. How to differentiate benign from malignant myometrial tumours using MR imaging. Eur Radiol 2013 ; 23 : 2306-14.
8) Tamai K, et al. The utility of diffusion-weighted MR imaging for differentiating uterine sarcomas from benign leiomyomas. Eur Radiol 2008 ; 18 : 723-30.
9) Namimoto T, et al. Combined use of T2-weighted and diffusion-weighted 3-T MR imaging for differentiating uterine sarcomas from benign leiomyomas. Eur Radiol 2009 ; 19 : 2756-64.
10) Kao YH, et al. Fluorine-18-fluorodeoxyglucose PET/CT for the evaluation of suspected recurrent uterine leiomyosarcomas. Acta Radiol 2011 ; 52 : 463-6.
11) Silverberg SG, Kurman RJ. Tumors of the uterine corpus. In : Silverberg SG, Kurman RJ, eds. Tumors of the Uterine Corpus and Gestational Trophoblastic Disease. 3rd ed. Washington DC : Armed Forces Institute of Pathology ; 1992. p.1-2.
12) Koyama T, et al. MR imaging of endometrial stromal sarcoma : correlation with pathologic findings. AJR Am J Roentgenol 1999 ; 173 : 767-72.
13) Furukawa R, et al. Endometrial stromal sarcoma located in the myometrium with a low-intensity rim on T2-weighted images : report of three cases and literature review. J Magn Reson Imaging 2010 ; 31 : 975-9.
14) Fujii S, et al. Diffusion-weighted imaging of uterine endometrial stromal sarcoma : a report of 2 cases. J Comput Assist Tomogr 2010 ; 34 : 377-9.
15) Huang YL, et al. Utility of diffusion-weighted and contrast-enhanced magnetic resonance imaging in diagnosing and differentiating between high- and low-grade uterine endometrial stromal sarcoma. Cancer Imaging 2019 ; 19 : 63.
16) Yoshizako T, et al. MR imaging of uterine adenosarcoma : case report and literature review. Magn Reson Med Sci 2011 ; 10 : 251-4.
17) Cornfeld D, et al. MRI appearance of mesenchymal tumors of the uterus. Eur J Radiol 2010 ; 74 : 241-9.
18) Lakhman Y, et al. Differentiation of uterine leiomyosarcoma from atypical leiomyoma : diagnostic accuracy of qualitative MR imaging features and feasibility of texture analysis. Eur Radiol 2017 ; 27 : 2903-15.
19) Takeuchi M, et al. Hyperintense uterine myometrial masses on T2-weighted magnetic resonance imaging : differentiation with diffusion-weighted magnetic resonance imaging. J Comput Assist Tomogr 2009 ; 33 : 834-7.
20) Kaganov H, et al. Preoperative magnetic resonance imaging diagnostic features of uterine leiomyosarcomas : a systematic review. Int J Technol Assess Health Care 2018 ; 34 : 172-9.
21) Davnall F, et al. Assessment of tumor heterogeneity : an emerging imaging tool for clinical practice? Insights Imag 2012 ; 3 : 573-89.
22) Tsujikawa T, et al. Assessment of intratumor heterogeneity in mesenchymal uterine tumor by an 18F-FDG PET/CT texture analysis. Ann Nucl Med 2017 ; 31 : 752-7.
23) Nishizawa S, et al. Incidence and characteristics of uterine leiomyomas with FDG uptake. Ann Nucl Med 2008 ; 22 : 803-10.
24) Tsujikawa T, et al. Uterine tumors : pathophysiologic imaging with 16alpha- [18F] fluoro-17beta-estradiol and 18F fluorodeoxyglucose PET : initial experience. Radiology 2008 ; 248 : 599-605.
25) Zhao Z, et al. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors : correlation with immunohistochemical analysis. J Nucl Med 2013 ; 54 : 499-506.
P.189 掲載の参考文献
1) 日本産科婦人科学会2017 年患者年報. http://plaza.umin.ac.jp/?jsog-go/new5.html.
2) Kapp DS, et al. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas. Cancer 2008 ; 112 : 820-30.
3) Seagle BL, et al. Prognosis and treatment of uterine leiomyosarcoma : a National Cancer Database study. Gynecol Oncol 2017 ; 145 : 61-70.
4) Si M, et al. Role of lymphadenectomy for uterine sarcoma : a meta-analysis. Int J Gynecol Oncol 2017 ; 27 : 109-16.
5) 日本婦人科腫瘍学会編. 子宮体がん治療ガイドライン 2018年版. 第7章 癌肉腫・肉腫の治療. 東京 : 金原出版 ; 2018. p.195-7.
6) Bai H, et al. Ovary and uterus-sparing procedures for low-grade endometrial stromal sarcoma : a retrospective study of 153 cases. Gynecol Oncol 2014 ; 132 : 654-60.
7) Leath CA 3rd, et al. A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol 2007 ; 105 : 630-4.
8) Lange S, et al. Prevalence of undiagnosed uterine leiomyosarcoma in women with undergoing hysterectomy or myomectomy for benign indications. Eur J Obstet Gynecol Reprod Biol 2017 ; 216 : 239-44.
9) Multinu F, et al. Incidence of sarcoma in patients undergoing hysterectomy for benign indications : a population-based study. Am J Onstet Gynecol 2019 ; 220 : 179. e1-10.
10) Wright JD, et al. Trends in use and outcomes of women undergoing hysterectomy with electric power morcellation. JAMA 2016 ; 316 : 877-8.
11) Giuntoli RL, et al. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol 2007 ; 106 : 82-8.
12) Cybulska P, et al. Seconadary surgical resection for patients with recurrent uterine leiomyosarcoma. Gynecol Oncol 2019 ; 154 : 333-7.
13) Bizzarri N, et al. Secondary cytoreductive surgery in recurrent uterine leiomyosarcoma : a multi-institutional study. Int J Gynecol Cancer 2019 ; 29 : 1134-40.
14) Omura GA, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas : a Gynecologic Oncology Group Study. J Clin Oncol 1985 ; 3 : 1240-5.
15) Santoro A, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas : a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995 ; 13 : 1537-45.
16) Judson I, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma : a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001 ; 37 : 870-7.
17) Hensley ML, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma : results of a phase II study. J Clin Oncol 2002 ; 20 : 2824-31.
18) Hensley ML, et al. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma : a Gynecologic Oncology Group phase II trial. Gynecol Oncol 2008 ; 109 : 329-34.
19) Hensley ML, et al. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma : a Gynecologic Oncology Group phase II trial. Gynecol Oncol 2008 ; 109 : 323-8.
20) Maki RG, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas : results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 2007 ; 25 : 2755-63.
21) Hensley ML, et al. Adjuvant therapy for high-grade, uterus-limited leiomyosarcma. Results of a phase 2 trial (SARC 005). Cancer 2013 ; 119 : 1555-61.
22) Hensley ML, et al. Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for high-grade uterine leiomyosarcoma : a phase III NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol 2018 ; 36 : 3324-30.
23) Schoffski P, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma : a randomized, open-label, multicenter, phase 3 trial. Lancet 2018 ; 387 : 1629-37.
24) Demitri GD, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy : results of a phase III randomized multicenter clinical trial. J Clin Oncol 2016 ; 34 : 786-93.
25) Amant F, et al. Clinical management of uterine sarcomas. Lancet Oncol 2009 ; 10 : 1188-98.
26) O'Cearbhaill R, et al. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecol Oncol 2010 ; 116 : 424-9.
27) George S, et al. Phase 2 trial of aromatase inhibition with letozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer 2014 ; 120 : 736-43.
28) Dahhan T, et al. The efficacy of hormonal treatment for residual or recurrent low-grade endometril stromal sarcoma : a retrospective study. Eur J Obstet Gynecol Reprod Biol 2009 ; 144 : 80-4.
29) Deshmukh U, et al. Adjuvant hormonal therapy for low-grade endometrial stromal sarcoma. Reprod Sci 2019 ; 26 : 600-8.
30) van der Graaf WT, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE) : a randomized, double-blind, placebo-controlled phase 3 trial. Lancet 2012 ; 379 : 1879-86.
31) McMeekin DS, et al. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis : a Gynecologic Oncology Group Study. Gynecol Oncol 2007 ; 106 : 596-603.
32) Hensley ML, et al. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma : an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol 2015 ; 33 : 1180-5.
33) Tap WD, et al. Olaratumab and doxorubicin versus doxorubicine alone for treatment of soft-tissue sarcoma : an open-label phase 1B and randomised phase 2 trial. Lancet 2016 ; 388 : 488-97.
34) Reed NS, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II : an European Organisation for Research and Treatment of Cancer Gynecological Cancer Group Study (protocol 55874). Eur J Cancer 2008 ; 44 : 808-18.

5章 卵巣癌

P.201 掲載の参考文献
1) 日本産科婦人科学会・日本病理学会編. 卵巣腫瘍取扱い規約 第1部 (組織分類ならびにカラーアトラス). 第2版. 東京 : 金原出版 ; 2009.
2) Prat J, for the FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynecol Obstet 2014 ; 124 : 1-5.
3) Kurman RJ, et al. Tumours of the ovary. WHO Classification of Tumours of the Female Reproductive Organs. Geneva : WHO Press ; 2014. p.11-86.
4) 日本産科婦人科学会・日本病理学会編. 卵巣腫瘍・卵管癌・腹膜癌取扱い規約 臨床編. 第1版. 東京 : 金原出版 ; 2015.
5) 日本産科婦人科学会・日本病理学会編. 卵巣腫瘍・卵管癌・腹膜癌取扱い規約 病理編. 第1版. 東京 : 金原出版 ; 2016.
6) 日本婦人科腫瘍学会編. 卵巣がん治療ガイドライン. 東京 : 金原出版 ; 2015.
7) Brierley JD, et al. UICC 日本委員会TNM委員会訳. TNM悪性腫瘍の分類. 第8版. 東京 : 金原出版 ; 2017.
8) Shappell HW, et al. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors : atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol 2002 ; 26 : 1529-41.
9) Seidman JD, et al. Epithelial tumors of the ovary. In : Kurman RJ, et al, editors. Blaustein's Pathology of the Female Gemital Tract. 7th ed. Switzerland : Springer ; 2019. p.948.
10) McGluggage WG, et al. Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma : recommendations from the international collaboration on cancer reporting (ICCR). Mod Pathol 2015 ; 28 : 101-22.
11) Trabert B, et al. Reported incidence and survival of fallopian tube carcinomas : a population-based analysis from the North American Association of Central Cancer Registries. J Natl Cancer Inst 2018 ; 110 : 750-7.
12) Torre LA, et al. Ovarian cancer statics, 2018. CA Cancer J Clin 2018 ; 68 : 284-96.
13) Samimi G. Population frequency of serous tubal intraepithelial carcinoma (STIC) in clinical practice using SEE-Fim Protocol. JNCI Cancer Spectr 2018 ; 2 : pky061.
14) Samimi G, et al. Processing of fallopian tube, ovary, and endometrial surgical pathology specimens : a survey of U. S. laboratory practices. Gynecol Oncol 2018 ; 148 : 515-20.
15) Gasimli K, et al. Lymph node involvement pattern and survival differences of FIGO IIIC and FIGO IIIA1 ovarian cancer patients after primary complete tumor debulking surgery : a 10-year retrospective analysis of the Tumor Bank Ovarian Cancer Network. Ann Surg Oncol 2016 ; 23 : 1279-86.
P.209 掲載の参考文献
1) Kurman RJ, et al. WHO Classification of Tumours of Female Reproductive Organs. 4th ed. Geneva : WHO Press ; 2014.
2) 日本産科婦人科学会・日本病理学会編. 卵巣腫瘍・卵管癌・腹膜癌取扱い規約 病理編. 東京 : 金原出版 ; 2016.
3) Kindelberger DW, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma : evidence for a causal relationship. Am J Surg Pathol 2007 ; 31 : 161-9.
4) Ahmed AA, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010 ; 221 : 49-56.
5) Kobel M, et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol 2010 ; 222 : 191-8.
7) Maeda D, et al. Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. Int J Mol Sci 2010 ; 11 : 5120-8.
8) Wiegand KC, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010 ; 363 : 1532-43.
9) McConechy MK, et al. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Mod Pathol 2014 ; 27 : 128-34.
P.216 掲載の参考文献
1) 日本産科婦人科学会・日本病理学会編. 卵巣腫瘍・卵管癌・腹膜癌取扱い規約 病理編. 東京 : 金原出版 ; 2016.
2) Adler E, et al. PAX8 expression in ovarian surface epithelial cells. Hum Pathol 2015 ; 46 : 948-56.
3) Kurman RJ, et al. WHO Classification of Tumours of Female Reproductive Organs. 4th ed. Geneva : WHO ; 2014.
5) Peres LC, et al. Invasive epithelial ovarian cancer survival by histotype and disease stage. J Natl Cancer Inst 2019 ; 111 : 60-8. doi : 10.1093/jnci/djy071.
6) Gurung A, et al. Molecular abnormalities in ovarian carcinoma : clinical, morphological and therapeutic correlates. Histopathology 2013 ; 62 : 59-70.
7) Seidman JD, et al. "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma : assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol Oncol 2011 ; 120 : 470-3.
8) Auersperg N, et al. Ovarian surface epithelium : biology, endocrinology, and pathology. Endocr Rev 2001 ; 22 : 255-88.
9) Auersperg N. The origin of ovarian carcinomas : a unifying hypothesis. Int J Gynecol Pathol 2011 ; 30 : 12-21.
10) Lim D, Oliva E. Precursors and pathogenesis of ovarian carcinoma. Pathology 2013 ; 45 : 229-42.
11) Nezhat FR, et al. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention. Am J Obstet Gynecol 2015 ; 213 : 262-7.
12) Rojas V, et al. Molecular characterization of epithelial ovarian cancer : implications for diagnosis and treatment. Int J Mol Sci 2016 ; 17 : 2113.
13) Hatina J, et al. Ovarian cancer stem cell heterogeneity. Adv Exp Med Biol 2019 ; 1139 : 201-21.
14) Cheng W, et al. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med 2005 ; 11 : 531-7.
15) Malpica A, Wong KK. The molecular pathology of ovarian serous borderline tumors. Ann Oncol 2016 ; 27 : i16-9. doi : 10.1093/annonc/mdw089.
16) Vang R, et al. Ovarian low-grade and high-grade serous carcinoma : pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009 16 : 267-82.
17) Ho CL, et al. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 2004 ; 64 : 6915-8.
18) Diaz-Padilla I, et al. Ovarian low-grade serous carcinoma : a comprehensive update. Gynecol Oncol 2012 ; 126 : 279-85.
19) Ki m J, et al. Cell origins of high-grade serous ovarian cancer. Cancers (Basel) 2018 ; 10 (11). pii : E433. doi : 10.3390/cancers10110433.
20) Morrison JC, et al. Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting : analysis of a case series. Am J Surg Pathol 2015 ; 39 : 442-53.
21) Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2017 ; 41 : 3-14.
22) Testa U, et al. Ovarian cancers : genetic abnormalities, tumor heterogeneity and progression, clonal evolution and cancer stem cells. Medicines (Basel) 2018 ; 5 : 16. doi : 10.3390/medicines5010016.
23) Kuhn E, et al. CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma : further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma. Mod Pathol 2016 ; 29 : 1254-61.
24) Yamamoto Y, et al. In vitro and in vivo correlates of physiological and neoplastic human fallopian tube stem cells. J Pathol 2016 ; 238 : 519-30.
25) Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011 ; 474 : 609-15.
26) Konecny GE, et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst 2014 ; 106 (10). pii : dju249. doi : 10.1093/jnci/dju249.
27) Kommoss S, et al. Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes. Clin Cancer Res 2017 ; 23 : 3794-801.
30) 国立がん研究センター. がん情報サービス「2017年のがん統計予測」.
31) Takaoka M, Miki Y. BRCA1 gene : function and deficiency. Int J Clin Oncol 2018 ; 23 : 36-44.
32) Mylavarapu S, et al. Role of BRCA mutations in the modulation of response to platinum therapy. Front Oncol 2018 ; 8 : 16.
33) Enomoto T, et al. The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer : CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE). Int J Gynecol Cancer 2019 ; 29 : 1043-9.
34) Zhong Q, et al. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival : a meta-analysis. Clin Cancer Res 2015 ; 21 : 211-20.
35) Seidman JD, et al. Surface epithelial tumors of the ovary. Kurman RJ, et al, editors. Blaustein's Pathology of the Female Genital Tract. 5th ed. New York : Springer ; 2002. p.791-904.
36) Shimada M, et al. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol 2009 ; 113 : 331-4.
37) Seidman JD, et al. Primary and metastatic mucinous adenocarcinomas in the ovaries. Am J Surg Pathol 2003 ; 27 : 985-93.
38) Kurman RJ, Shih IeM. The dualistic model of ovarian carcinogenesis. Am J Pathol 2016 ; 186 : 733-47.
39) Wang Y, et al. Clonally analysis of combined Brenner and mucinous tumors of the ovary reveals their monoclonal origin. J Pathol 2015 ; 23 : 146-51.
40) Cheasley D, et al. The molecular origin and taxonomy of mucinous ovarian carcinoma. Nat Commun 2019 ; 10 : 3935.
41) Mackenzie R, et al. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. BMC Cancer 2015 ; 15 : 415.
42) Mackenzie R, et al. Morphologic and molecular characteristics of mixed epithelial ovarian cancers. Am J Surg Pathol 2015 ; 39 : 1548-57.
43) Brown J, Frumovitz M. Mucinous tumors of the ovary : current thoughts on diagnosis and management. Curr Oncol Rep 2014 ; 16 : 389.
44) Ryland GL, et al. Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. Gen Med 2015 ; 7 : 87.
45) Ryland GL, et al. RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary. J Pathol 2013 ; 229 : 469-76.
46) Heinzelmann-Schwarz VA, et al. PMA distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer 2006 ; 94 : 904-13.
47) Hunter SM, et al. Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations. Clin Cancer Res 2012 ; 18 : 5267-77. doi : 10.1158/1078-0432.CCR-12-1103.
P.221 掲載の参考文献
1) Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011 ; 474 : 609-15.
2) Bulun SE, et al. Epithelial mutations in endometriosis : link to ovarian cancer. Endocrinology 2019 ; 160 : 626-38.
3) Pearce CL, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer : a pooled analysis of case-control studies. Lancet Oncol 2012 ; 13 : 385-94.
5) Wiegand KC, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010 ; 363 : 1532-43.
6) Sugino K, et al. Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients. Sci Rep 2019 ; 9 : 17808.
7) Murakami R, et al. Exome sequencing landscape analysis in ovarian clear cell carcinoma shed light on key chromosomal regions and mutation gene networks. Am J Pathol 2017 ; 187 : 2246-58.
8) Suda K, et al. Clonal expansion and diversification of cancer-associated mutations in endometriosis and normal endometrium. Cell Reports 2018 ; 24 : 1777-89.
9) Yamamoto S, et al. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. J Pathol 2011 ; 225 : 189-94.
10) Anglesio MS, et al. Cancer-associated mutations in endometriosis without cancer. N Engl J Med 2017 ; 376 : 1835-48.
11) Cochrane DR, et al. Clear cell and endometrioid carcinomas : are their differences attributable to distinct cells of origin? J Pathol 2017 ; 243 : 26-36.
13) Rosario R, et al. The role of FOXL2 in the pathogenesis of adult ovarian granulosa cell tumours. Gynecol Oncol 2014 ; 133 : 382-7.
14) Pilsworth JA, et al. TERT promoter mutation in adult granulosa cell tumor of the ovary. Mod Pathol 2018 ; 31 : 1107-15.
15) Cooke SL, et al. The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma. Clin Cancer Res 2017 ; 23 : 7633-40.
16) Tamura R, et al. XCL1 expression correlates with CD8-positive T cells infiltration and PD-L1 expression in squamous cell carcinoma arising from mature cystic teratoma of the ovary. Oncogene 2020 ; 39 : 3541-54.
P.227 掲載の参考文献
1) 日本婦人科腫瘍学会編. 卵巣がん治療ガイドライン 2015年版. 東京 ; 金原出版 ; 2015.
2) du Bois A, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer : a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials : by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009 ; 115 : 1234-44.
3) Maggioni A, et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer 2006 ; 95 : 699-704.
4) Panici PB, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer : a randomized clinical trial. J Natl Cancer Inst 2005 ; 97 : 560-6.
5) du Bois A, et al. Potential role of lymphadenectomy in advanced ovarian cancer : a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol 2010 ; 28 : 1733-9.
6) Harter P, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med 2019 ; 380 : 822-32.
7) Vergote I, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010 ; 363 : 943-53.
8) Kehoe S, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS) : an open-label, randomised, controlled, non-inferiority trial. Lancet 2015 ; 386 : 249-57.
9) Onda T, et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial : Japan Clinical Oncology Group Study JCOG0602. Eur J Cancer 2016 ; 64 : 22-31.
10) Fagotti A, et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial) : final analysis of peri-operative outcome. Eur J Cancer 2016 ; 59 : 22-33.
11) Onda T, et al. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. Eur J Cancer 2020 ; 130 : 114-25.
12) Alexi A, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer : Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016 ; 34 : 3460-73.
13) van de Laar R, et al. External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer. Gynecol Oncol 2015 ; 137 : 210-5.
14) Fagotti A, et al. A multicentric trial (Olympiae MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer. Am J Obstet Gynecol 2013 ; 209 : 462. e1-11.
15) Brun JL, et al. External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers : clues for a simplified score. Gynecol Oncol 2008 ; 110 : 354-9.
16) Rutten MJ, et al. Laparoscopy to predict the result of primary cytoreductive surgery in patients with advanced ovarian cancer : a randomized controlled trial. J Clin Oncol 2017 ; 35 : 613-21.
17) Nagarsheth NP, et al. The incidence of port-site metastases in gynecologic cancers. JSLS 2004 ; 8 : 133-9.
18) Rouzier R, et al. Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer : results from the ANTHALYA trial. Eur J Cancer 2017 ; 70 : 133-42.
19) Coleman RL, et al. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med 2019 ; 381 : 1929-39.
20) National Comprehensive Cancer Network. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer (Version 1.2019). Available from : https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf
21) Falcetta FS, et al. Laparoscopy versus laparotomy for FIGO stage I ovarian cancer. Cochrane Database Syst Rev 2016 ; 10 : CD005344.
P.236 掲載の参考文献
1) Katsumata N, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer : a phase 3, open-label, randomised controlled trial. Lancet 2009 ; 374 : 1331-8.
2) Clamp AR, et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8) : primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet 2019 ; 394 : 2084-95.
3) Chan JK, et al. Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med 2016 ; 374 : 738-48.
4) Burger RA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011 ; 365 : 2473-83.
5) Perren TJ, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011 ; 365 : 2484-96.
6) Moore K, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018 ; 379 : 2495-505.
7) Parmar MK, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer : the ICON4/AGO-OVAR-2.2 trial. Lancet 2003 ; 361 : 2099-106.
8) Pujade-Lauraine E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010 ; 28 : 3323-9.
9) Pfisterer J, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer : an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006 ; 24 : 4699-707.
10) Aghajanian C, et al. OCEANS : a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012 ; 30 : 2039-45.
11) Coleman RL, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213) : a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2017 ; 18 : 779-91.
12) Pujade-Lauraine E, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21) : a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017 ; 18 : 1274-84.
13) Pujade-Lauraine E, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer : The AURELIA open-label randomized phase III trial. J Clin Oncol 2014 ; 32 : 1302-8.
P.242 掲載の参考文献
1) Gonzalez-Martin A, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019 ; 381 : 2391-402.
2) Coleman RL, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med 2019 ; 381 : 2403-15.
3) Mirza MR, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016 ; 375 : 2154-64.
4) Fong PC, et al. Poly (ADP) -ribose polymerase inhibition : frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010 ; 28 : 2512-9.
5) Pujade-Lauraine E, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer : The AURELIA open-label randomized phase III trial. J Clin Oncol 2014 ; 32 : 1302-8.
6) Oza AM, et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation : integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol 2017 ; 147 : 267-75.
7) Sandhu SK, et al. The poly (ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer : a phase 1 dose-escalation trial. Lancet Oncol 2013 ; 14 : 882-92.
8) Hamanishi J, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 2015 ; 33 : 4015-22.
P.247 掲載の参考文献
1) 日本産科婦人科学会・日本病理学会編. 卵巣腫瘍・卵管癌・腹膜癌取扱い規約 病理編. 東京 : 金原出版 ; 2016.
2) Kobayashi H, et al. The conceptual advances of carcinogenic sequence model in high-grade serous ovarian cancer. Biomed Rep 2017 ; 7 : 209-13.
4) 日本婦人科腫瘍学会編. 卵巣がん治療ガイドライン 2015年版. 東京 : 金原出版 ; 2015.
5) Aletti GD, et al. Pattern of retroperitoneal dissemination of primary peritoneal cancer : basis for rational use of lymphadenectomy. Gynecol Oncol 2009 ; 114 : 32-6.
6) Eisenhauer EL, et al. Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma : matched-case comparison with patients with epithelial ovarian carcinoma. Am J Obstet Gynecol 2008 ; 198 : 213. e1-7.
7) Baekelandt M, et al. Carcinoma of the fallopian tube. Cancer 2000 ; 89 : 2076-84.
P.257 掲載の参考文献
1) Taylor HC. Malignant and semimalignant tumours of the ovary. Surg Gynecol Obstet 1929 ; 48 : 204-30.
2) International Federation of Gynecology and Obstetrics. Classification and staging of malignant tumours in female pelvis. Acta Obstet Gynecol Scand 1971 ; 50 : 1-7.
3) Serov SF, et al. Histological typing of ovarian tumours. In : WHO International Histological Classification of Tumours. vol 9. Geneva : World Health Organization ; 1973. p.37-52.
4) Scully RE, et al. Histological typing of ovarian tumors. In : WHO International Histological Classification of Tumors. 2nd ed. Berlin, Heidelberg : Springer-Verlag ; 1999.
5) Kurman RJ, et al. WHO Classification of Tumours of Female Reproductive Organs. Lyon : International Agency for Research on Cancer (IARC) ; 2014.
6) Longracre TA, et al. Ovarian serous tumors of low malignant potential (borderline tumors) : outcome-based study of 276 patients with long-term ( > or=5-year) follow-up. Am J Surg Pathol 2005 ; 29 : 707-23.
7) Wang Y, et al. Clonality analysis of combined Brenner and mucinous tumours of the ovary reveals their monoclonal origin. J Pathol 2015 ; 237 : 146-51.
8) Maeda D, et al. Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms. Adv Anat Pathol 2013 ; 20 : 45-52.
9) Uzan C, et al. Management and prognosis of borderline ovarian Brenner tumors. Int J Gynecol Cancer 2012 ; 22 : 1332-6.
10) Kuhn E, et al. The pathogenesis of atypical proliferative Brenner tumor : an immunohistochemical and molecular genetic analysis. Mod Pathol 2014 ; 27 : 231-7.
11) Kolwijck E, et al. Preoperative CA125 levels in 123 patients with borderline ovarian tumours. Int J Gynecol Cancer 2009 ; 19 : 342-9.
12) Gershenson DM. Clinical management potential tumours of low malignancy. Best Pract Res Clin Obstet Gynaecol 2002 ; 16 : 513-27.
13) Song T, et al. Accuracy of frozen section diagnosis of borderline ovarian tumours. Gynecol Oncol 2011 ; 122 : 261-6.
14) Fauvet R, et al. Restaging surgery for women with borderline ovarian tumours. Cancer 2004 ; 100 : 1145-51.
15) Morice P, et al. Clinical outcomes and fertility after conservative treatment of ovarian borderline tumours. Fertil Steril 2001 ; 75 : 92-6.
16) Silva EG, et al. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Am J Surg Pathol 2006 ; 30 : 1367-71.
17) du Bois A, et al. Borderline tumors of the ovary : a systematic review [German]. Geburtsh Frauenheilk 2009 ; 69 : 807-33.
18) Sobiczewski P, et al. The evaluation of risk factors associated with relapse and recurrence of borderline ovarian tumours with long-term floow-up. Int J Gynecol Cancer 2016 ; 26 : 1053-61.
19) du Bois A, et al. Borderline tumours of the ovary : a cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) Study Group. Eur J Cancer 2013 ; 49 : 1905-14.

6章 絨毛性疾患

P.270 掲載の参考文献
1) 日本産科婦人科学会・日本病理学会編. 絨毛性疾患取扱い規約. 第3版. 東京 : 金原出版 ; 2011.
2) Kurman RJ, et al, editors. WHO Classification of Tumours of Female Reproductive Organs. 4th ed. Lyon : International Agency for Research on Cancer ; 2014.
3) Kihara M, et al. Genetic origin and imprinting in hydatidiform moles. Comparison between DNA polymorphism analysis and immunoreactivity of p57KIP2. J Reprod Med 2005 ; 50 : 307-12.
4) Wang CM, et al. Identification of 13 novel NLRP7 mutations in 20 families with recurrent hydatidiform mole : missense mutations cluster in the leucin-rich region. J Med Genet 2009 ; 46 : 569-75.
5) Kaiser-Rogers KA, et al. Androgenetic/biparental mosaicism causes placental mesenchymal dysplasia. J Med Genet 2006 ; 43 : 187-92.
6) Jitsumori S, et al. Placental mesenchymal dysplasia with severe fetal growth restriction in one placenta of a dichorionic diamniotic twin pregnancy. J Obstet Gynaecol Res 2018 ; 44 : 951-4.
7) Shih IM, et al. The pathology of intermediate trophoblastic tumors and tumor-like lesions. Int J Gynecol Pathol 2001 ; 20 : 31-47.
8) Shih IM, et al. Epithelioid trophoblastic tumor : a neoplasm distinct from choriocarcinoma and placental site trophoblastic tumor simulating carcinoma. Am J Surg Pathol 1998 ; 22 : 1393-403.
9) Allison KH, et al. Epithelioid trophoblastic tumor : review of a rare neoplasm of the chorionic-type intermediate trophoblast. Arch Pathol Lab Med 2006 ; 130 : 1875-7.
10) Stichelbout M, et al. SALL4 expression in gestational trophoblastic tumors : a useful tool to distinguish choriocarcinoma from placental site trophoblastic tumor and epithelioid trophoblastic tumor. Hum Pathol 2016 ; 54 : 121-6.
P.283 掲載の参考文献
1) 日本産科婦人科学会・日本病理学会編. 絨毛性疾患取扱い規約. 第3版. 東京 : 金原出版 ; 2011.
2) 竹内正七. 絨毛性疾患登録委員会報告 : I. 絨毛性疾患の分類・定義・診断基準, II. 絨毛性疾患地域登録成績, III. 侵入奇胎・絨毛癌についての全国病院登録成績. 日産婦誌 1987 ; 39 : 871-80.
3) 石塚直隆ほか. 絨毛癌と侵入奇胎の臨床的診断に関する「絨毛癌診断スコア」の検討. 日産婦誌 1984 ; 36 : 459-62.
4) Kohorn EI, et al. Workshop report : combining the staging system of the International Federation of Gynecology and Obstetrics with the scoring system of the World Heath Organization for Trophoblastic Neoplasia. Report of the Working Committee of the International Society for the Study of Trophoblastic Disease and the International Gynecologic Cancer Society. Int J Gynecol Cancer 2000 ; 10 : 84-8.
5) Ngan HY. The practicability of FIGO 2000 staging for gestational trophoblastic neoplasia. Int J Gynecol Cancer 2004 ; 14 : 202-5.
6) Horowitz NS, et al. Placental site trophoblastic tumors and epithelioid trophoblastic tumors : biology, natural history, and treatment modalities. Gynecol Oncol 2017 ; 144 : 208-14.
7) Lurain JR. Gestational trophoblastic disease I : epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol 2010 ; 203 : 531-9.
8) Seckl MJ, et al. Gestational trophoblastic disease. Lancet 2010 ; 376 : 717-29.
9) Sand PK, et al. Repeat gestational trophoblastic disease. Obstet Gynecol 1984 ; 63 : 140-4.
10) Martin BH, Kim JH. Changes in gestational trophoblastic tumors over four decades. A Korean experience. J Reprod Med 1998 ; 43 : 60-8.
11) Schmitt C, et al. Risk of gestational trophoblastic neoplasia after hCG normalisation according to hydatidiform mole type. Gynecol Oncol 2013 ; 130 : 86-9.
12) 友田豊, 後藤節子. 胞状奇胎娩出後の登録管理. 絨毛性疾患の診断と治療. 大阪 : 永井書店 ; 1996. p.19-35.
13) Sebire NJ, et al. Outcome of twin pregnancies with complete hydatidiform mole and healthy co-twin. Lancet 2002 ; 359 : 2165-6.
14) Khanlian SA, et al. Persistent low levels of human chorionic gonadotropin : a premalignant gestational trophoblastic disease. Am J Obstet Gynecol 2003 ; 188 : 1254-9.
15) Cole LA, Muller CY. Hyperglycosylated hCG in the management of quiescent and chemorefractory gestational trophoblastic diseases. Gynecol Oncol 2010 ; 116 : 3-9.
P.293 掲載の参考文献
1) 井箟一彦. 難治性絨毛性疾患の治療. 日本婦人科腫瘍学会雑誌 2011 ; 29 : 655-62.
2) 日本産科婦人科学会婦人科腫瘍委員会絨毛性疾患地域登録成績. http://plaza.umin.ac.jp/?jsog-go/new5.html
3) 日本産科婦人科学会・日本病理学会編. 絨毛性疾患取扱い規約. 第3版. 東京 : 金原出版 ; 2011.
4) 日本婦人科腫瘍学会編. 子宮体がん治療ガイドライン 2018年版. 東京 : 金原出版 ; 2018. p.203-21.
5) Berkowitz RS, Goldstein DP. Clinical practice. Molar pregnancy. N Engl J Med 2009 ; 360 : 1639-45.
6) Padron L, et al. Manual compared with electric vacuum aspiration for treatment of molar pregnancy. Obstet Gynecol 2018 ; 131 : 652-9.
7) Usui H, et al. Gestational trophoblastic neoplasia from genetically confirmed hydatidiform moles : prospective observational cohort study. Int J Gynecol Cancer 2018 ; 28 : 1772-80.
8) Albright BB, et al. Gestational trophoblastic neoplasia after human chorionic gonadotropin normalization following molar pregnancy : a systematic review and meta-analysis. Obstet Gynecol 2020 ; 135 : 12-23.
9) 佐藤明日香ほか. 胞状奇胎自然寛解後の妊娠予後. 産婦人科の実際 2018 ; 67 : 895-900.
10) Zhao P, et al. Total hysterectomy versus uterine evacuation for preventing post-molar gestational trophoblastic neoplasia in patients who are at least 40 years old : a systematic review and meta-analysis. BMC Cancer 2019 ; 19 : 13.
11) Seckl M. Time to stop offering prophylactic chemotherapy after molar pregnancies? BJOG 2014 ; 121 : 1420.
12) Wang Q, et al. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. Cochrane Database Syst Rev 2017 ; 9 : CD007289.
13) Lawrie TA, et al. First-line chemotherapy in low-risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev 2016 ; 6 : CD007102.
14) Newlands ES, et al. Developments in chemotherapy for medium- and high-risk patients with gestational trophoblastic tumours (1979-1984). Br J Obstet Gynaecol 1986 ; 93 : 63-9.
15) Sato S, et al. The efficacy and toxicity of 4-day chemotherapy with methotrexate, etoposide and actinomycin D in patients with choriocarcinoma and high-risk gestational trophoblastic neoplasia. Int J Clin Oncol 2020 ; 25 : 203-9. 2019.
16) Sita-Lumsden A, et al. Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000-2009. Br J Cancer 2012 ; 107 : 1810-4.
17) Chan Wah Hak C, et al. Emergency etoposide-cisplatin (Em-EP) for patients with germ cell tumours (GCT) and trophoblastic neoplasia (TN). BMC Cancer 2019 ; 19 : 770.
18) Newlands ES, Bagshawe KD. Anti-tumour activity of the epipodophyllin derivative VP16-213 (etoposide : NSC-141540) in gestational choriocarcinoma. Eur J Cancer 1980 ; 16 : 401-5.
19) Newlands ES, et al. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol 2000 ; 18 : 854-9.
20) Wang J, et al. Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). Ann Oncol 2008 ; 19 : 1578-83.
21) Matsui H, et al. Salvage combination chemotherapy with 5-fluorouracil and actinomycin D for patients with refractory, high-risk gestational trophoblastic tumors. Cancer 2002 ; 95 : 1051-4.
22) Fleming EL, et al. The changing role of thoracotomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center. J Reprod Med 2008 ; 53 : 493-8.
23) Alifrangis C, et al. EMA/CO for high-risk gestational trophoblastic neoplasia : good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol 2013 ; 31 : 280-6.
24) Jiao L, et al. Intraplacental choriocarcinoma : systematic review and management guidance. Gynecol Oncol 2016 ; 141 : 624-31.
25) Froeling FEM, et al. Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours. Br J Cancer 2019 ; 120 : 587-94.
26) Chiofalo B, et al. Fertility sparing strategies in patients affected by placental site trophoblastic tumor. Curr Treat Options Oncol 2017 ; 18 : 58.
27) Ishida Y, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992 ; 11 : 3887-95.
28) Lu B, et al. Analysis of PD-L1 expression in trophoblastic tissues and tumors. Hum Pathol 2019 ; 84 : 202-12.
29) Huang M, et al. Complete serologic response to pembrolizumab in a woman with chemoresistant metastatic choriocarcinoma. J Clin Oncol 2017 ; 35 : 3172-4.
30) Ghorani E, et al. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia. Lancet 2017 ; 390 : 2343-5.

7章 患者への医療的サポート, こころのケア

P.304 掲載の参考文献
1) Dargent D, et al. Laparoscopic vaginal radical trachelectomy : a treatment to preserve the fertility of cervical carcinoma patients. Cancer 2000 ; 88 : 1877-82.
2) Smith JR, et al. Abdominal radical trachelectomy : a new surgical technique for the conservative management of cervical carcinoma. Br J Obstet Gynaecol 1997 ; 104 : 1196-200.
3) Sato S, et al. Questionnaire survey of the current status of radical trachelectomy in Japan. Int J Clin Oncol 2011 ; 16 : 141-4.
4) Kunieda F, et al. Gynecologic Cancer Study Group of the Japan Clinical Oncology Group. Non-randomized confirmatory trial of modified radical hysterectomy for patients with tumor diameter 2 cm or less FIGO Stage IB1 uterine cervical cancer : Japan Clinical Oncology Group Study (JCOG1101). Jpn J Clin Oncol 2015 ; 45 : 123-6.
5) Song Y, et al. Efficacy of neoadjuvant platinum-based chemotherapy during the second and third trimester of pregnancy in women with cervical cancer : an updated systematic review and meta-analysis. Drug Des Devel Ther 2018 ; 13 : 79-102.
6) Yoshihara K, et al. The safety and effectiveness of abdominal radical trachelectomy for early-stage cervical cancer during pregnancy. Int J Gynecol Cancer 2018 ; 28 : 782-7.
7) Bokhman JV, et al. Can primary endometrial carcinoma stage I be cured without surgery and radiation therapy? Gynecol Oncol 1985 ; 20 : 139-55.
8) Ushijima K, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007 ; 25 : 2798-803.
9) Shiomi M, et al. Endometrial carcinoma in a gravid uterus : a case report and literature review. BMC Pregnancy Childbirth 2019 ; 19 : 425.
10) Koskas M, et al. Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma : systematic review and meta-analysis. Fertil Steril 2014 ; 101 : 785-94.
11) Mitsuhashi A, et al. Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients. J Gynecol Oncol 2019 ; 30 : e90.
12) Colombo N, et al. Controversial issues in the management of early epithelial ovarian cancer : conservative surgery and role of adjuvant therapy. Gynecol Oncol 1994 ; 55 : S47-51.
13) Satoh T, et al. Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer : a proposal for patient selection. J Clin Oncol 2010 ; 28 : 1727-32.
14) Newton C, et al. A multicentre retrospective cohort study of ovarian germ cell tumours : evidence for chemotherapy de-escalation and alignment of paediatric and adult practice. Eur J Cancer 2019 ; 113 : 19-27.
15) Satoh T, et al, Gynecologic Cancer Study Group of the Japan Clinical Oncology Group. A non-randomized confirmatory study regarding selection of fertility-sparing surgery for patients with epithelial ovarian cancer : Japan Clinical Oncology Group Study (JCOG1203). Jpn J Clin Oncol 2015 ; 45 : 595-9.
16) Uzan C, et al. Outcomes after conservative treatment of advanced-stage serous borderline tumors of the ovary. Ann Oncol 2010 ; 21 : 55-60.
17) Nasioudis D, et al. Safety of fertility-sparing surgery for premenopausal women with sex cord-stromal tumors confined to the ovary. Int J Gynecol Cancer 2017 ; 27 : 1826-32.
18) Brannstrom M, et al. Livebirth after uterus transplantation : authors' reply. Lancet 2015 ; 385 : 2352-3.
Amant F, et al. Gynecologic cancers in pregnancy : guidelines based on a third international consensus meeting. Ann Oncol 2019 ; 30 : 1601-1612. doi : 10.1093/annonc/mdz228.
P.316 掲載の参考文献
1) Global Burden of Disease Cancer Collaboration, Fitzmaurice C, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016 : A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol 2018 ; 4 : 1553-68.
2) Steliarova-Foucher E, et al, IICC-3 contributors. International incidence of childhood cancer, 2001-10 : a population-based registry study. Lancet Oncol 2017 ; 18 : 719-31.
3) Wallace WH, et al. Fertility preservation for girls and young women with cancer : population-based validation of criteria for ovarian tissue cryopreservation. Lancet Oncol 2014 ; 15 : 1129-36.
4) Peate M, et al. The fertility-related concerns, needs and preferences of younger women with breast cancer : a systematic review. Breast Cancer Res Treat 2009 ; 116 : 215-23.
5) Logan S, et al. Systematic review of fertility-related psychological distress in cancer patients : informing on an improved model of care. Psychooncology 2019 ; 28 : 22-30.
6) Faddy MJ, Gosden RG. A model conforming the decline in follicle numbers to the age of menopause in women. Hum Reprod 1996 ; 11 : 1484-6.
7) Broekmans FJ, et al. Female reproductive ageing : current knowledge and future trends. Trends Endocrinol Metab 2007 ; 18 : 58-65.
8) Broekmans FJ, et al. Ovarian aging : mechanisms and clinical consequences. Endocr Rev 2009 ; 30 : 465-93.
9) Wallace WH, Kelsey TW. Human ovarian reserve from conception to the menopause. PLoS One 2010 ; 5 : e8772.
10) Lee SJ, et al, American Society of Clinical Oncology. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006 ; 24 : 2917-31.
11) Rodriguez-Wallberg KA, Oktay K. Recent advances in oocyte and ovarian tissue cryopreservation and transplantation. Best Pract Res Clin Obstet Gynaecol 2012 ; 26 : 391-405.
12) Loren AW, et al, American Society of Clinical Oncology. Fertility preservation for patients with cancer : American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013 ; 31 : 2500-10.
13) Green DM, et al. The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure : a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 2014 ; 61 : 53-67.
14) Bines J, et al. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996 ; 14 : 1718-29.
15) Wallace WH, et al. Fertility preservation for young patients with cancer : who is at risk and what can be offered? Lancet Oncol 2005 ; 6 : 209-18.
16) Meirow D, et al. Administration of cyclophosphamide at different stages of follicular maturation in mice : effects on reproductive performance and fetal malformations. Hum Reprod 2001 ; 16 : 632-7.
17) Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 2007 ; 110 : 2222-9.
18) Ben-Aharon I, et al. Chemotherapy-induced ovarian failure as a prototype for acute vascular toxicity. Oncologist 2012 ; 17 : 1386-93.
19) Meistrich ML. Effects of chemotherapy and radiotherapy on spermatogenesis in humans. Fertil Steril 2013 ; 100 : 1180-6.
20) Meistrich ML. Male gonadal toxicity. Pediatr Blood Cancer 2009 ; 53 : 261-6.
21) Gandini L, et al. Effect of chemo- or radiotherapy on sperm parameters of testicular cancer patients. Hum Reprod 2006 ; 21 : 2882-9.
22) Anderson RA, et al. Cancer treatment and gonadal function : experimental and established strategies for fertility preservation in children and young adults. Lancet Diabetes Endocrinol 2015 ; 3 : 556-67.
23) Wallace WH, et al. Male fertility in long-term survivors of childhood acute lymphoblastic leukaemia. Int J Androl 1991 ; 14 : 312-9.
24) Gerl A, et al. The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer 2001 ; 91 : 1297-303.
25) Williams DH, et al. Pretreatment semen parameters in men with cancer. J Urol 2009 ; 181 : 736-40.
26) Wallace WH, et al. The radiosensitivity of the human oocyte. Hum Reprod 2003 ; 18 : 117-21.
27) Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 2001 ; 7 : 535-43.
28) Irtan S, et al. Ovarian transposition in prepubescent and adolescent girls with cancer. Lancet Oncol 2013 ; 14 : e601-8.
29) Littley MD, et al. Radiation-induced hypopituitar ism is dose-dependent. Clin Endocrinol (Oxf) 1989 ; 31 : 363-73.
30) Hall JE, et al. Potential for fertility with replacement of hypothalamic gonadotropin-releasing hormone in long term female survivors of cranial tumors. J Clin Endocrinol Metab 1994 ; 79 : 1166-72.
31) Shalet SM, et al. Vulnerability of the human Leydig cell to radiation damage is dependent upon age. J Endocrinol 1989 ; 120 : 161-5.
32) Castillo LA, et al. Gonadal function after 12-Gy testicular irradiation in childhood acute lymphoblastic leukaemia. Med Pediatr Oncol 1990 ; 18 : 185-9.
33) Schuring AN, et al. Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I : indications for fertility preservation. Arch Gynecol Obstet 2018 ; 297 : 241-55.
34) Oktay K, et al. Fertility preservation in patients with cancer : ASCO clinical practice guideline update. J Clin Oncol 2018 ; 36 : 1994-2001.
35) von Wolff M, et al. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril 2009 ; 92 : 1360-5.
36) Shalom-Paz E, et al. Fertility preservation for breast-cancer patients using IVM followed by oocyte or embryo vitrification. Reprod Biomed Online 2010 ; 21 : 566-71.
37) Das M, et al. Ovarian reserve and response to IVF and in vitro maturation treatment following chemotherapy. Hum Reprod 2012 ; 27 : 2509-14.
38) Oktay K, et al. Fertility preservation in breast cancer patients : a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005 ; 23 : 4347-53.
39) Azim AA, et al. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer : a prospective controlled study. J Clin Oncol 2008 ; 26 : 2630-5.
40) Oktay K, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab 2006 ; 91 : 3885-90.
41) Tatsumi T, et al. No increased risk of major congenital anomalies or adverse pregnancy or neonatal outcomes following letrozole use in assisted reproductive technology. Hum Reprod 2017 ; 32 : 125-32.
42) Cobo A, et al. Is vitrification of oocytes useful for fertility preservation for age-related fertility decline and in cancer patients? Fertil Steril 2013 ; 99 : 1485-95.
43) Goldman RH, et al. Predicting the likelihood of live birth for elective oocyte cryopreservation : a counseling tool for physicians and patients. Hum Reprod 2017 ; 32 : 853-9.
44) Cobo A, et al. Oocyte vitrification as an efficient option for elective fertility preservation. Fertil Steril 2016 ; 105 : 755-64. e8.
45) Donnez J, Dolmans MM. Fertility preservation in women. N Engl J Med 2017 ; 377 : 1657-65.
46) Van der Ven H, et al. Ninety-five orthotopic transplantations in 74 women of ovarian tissue after cytotoxic treatment in a fertility preservation network : tissue activity, pregnancy and delivery rates. Hum Reprod 2016 ; 31 : 2031-41.
47) Jensen AK, et al. Outcomes of transplantations of cryopreserved ovarian tissue to 41 women in Denmark. Hum Reprod 2015 ; 30 : 2838-45.
48) Oktay K, et al. Fertility preservation in patients with cancer : ASCO clinical practice guideline update. J Clin Oncol 2018 ; 36 : 1994-2001.
49) Yasmin E, et al, British Fertility Society. Fertility preservation for medical reasons in girls and women : British fertility society policy and practice guideline. Hum Fertil (Camb) 2018 ; 21 : 3-26.
50) Suzuki N. Clinical practice guidelines for fertility preservation in pediatric, adolescent, and young adults with cancer. Int J Clin Oncol 2019 ; 24 : 20-7.
51) Practice Committee of the American Society for Reproductive Medicine. Electronic address : asrm@asrm.org. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy : a committee opinion. Fertil Steril 2019 ; 112 : 1022-33.
52) Dolmans MM, et al. Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue. Fertil Steril 2013 ; 99 : 1514-22.
53) Dolmans MM, et al. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood 2010 ; 116 : 2908-14.
54) Balduzzi A, et al. Fertility preservation issues in pediatric hematopoietic stem cell transplantation : practical approaches from the consensus of the Pediatric Diseases Working Party of the EBMT and the International BFM Study Group. Bone Marrow Transplant 2017 ; 52 : 1406-15.
55) Shapira M, et al. First delivery in a leukemia survivor after transplantation of cryopreserved ovarian tissue, evaluated for leukemia cells contamination. Fertil Steril 2018 ; 109 : 48-53.
56) 日本産科婦人科学会施設検索. 施設一覧. http://www.jsog.or.jp/facility_program/search_result_facility.php
57) Feldschuh J, et al. Successful sperm storage for 28 years. Fertil Steril 2005 ; 84 : 1017.
58) Berookhim BM, Mulhall JP. Outcomes of operative sperm retrieval strategies for fertility preservation among males scheduled to undergo cancer treatment. Fertil Steril 2014 ; 101 : 805-11.
59) Gupta AA, et al. Testicular biopsy for fertility preservation in prepubertal boys with cancer : identifying preferences for procedure and reactions to disclosure practices. J Urol 2016 ; 196 : 219-24.
60) Sanada Y, et al. A Japanese nationwide survey on the cryopreservation of embryos, oocytes and ovarian tissue for cancer patients. J Obstet Gynaecol Res 2019 ; 45 : 2021-8.
61) Takahashi Y, et al. Current multidisciplinary approach to fertility preservation for breast cancer patients. Acta Med Okayama 2018 ; 72 : 137-42.
62) Salama M, et al. A successful multidisciplinary approach for treatment and for preserving the reproductive potential in a rare case of acute lymphocytic leukemia during pregnancy. Gynecol Endocrinol 2019 ; 35 : 115-8.
63) Salama M, et al. Preserving fertility in female patients with hematological malignancies : a multidisciplinary oncofertility approach. Ann Oncol 2019 ; 30 : 1760-75.
64) Ben-Aharon I, et al. Optimizing the process of fertility preservation in pediatric female cancer patients : a multidisciplinary program. BMC Cancer 2016 ; 16 : 620.
65) Laronda MM. Engineering a bioprosthetic ovary for fertility and hormone restoration. Theriogenology 2020 Jan 11. pii : S0093-691X (20) 30027-3.
66) Dolmans MM, Amorim CA. FERTILITY PRESERVATION : Construction and use of artificial ovaries. Reproduction 2019 ; 158 : F15-25.
67) McLaughlin M, et al. Metaphase II oocytes from human unilaminar follicles grown in a multi-step culture system. Mol Hum Reprod 2018 ; 24 : 135-42.
P.323 掲載の参考文献
1) 日本老年医学会. 高齢者の定義と区分に関して. https://www.jpn-geriat-soc.or.jp/proposal/pdf/definition_01.pdf
2) 日本産科婦人科学会婦人科腫瘍委員会報告. 2017年度患者年報. 日産婦誌 2019 ; 71 : 669-724.
3) Hamel MB, et al. Surgical outcomes for patients aged 80 and older : morbidity and mortality from major noncardiac surgery. J Am Geriatr Soc 2005 ; 53 : 424-9.
4) Turrentine FE, et al. Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg 2006 ; 203 : 865-77.
5) Winter WE 3rd, et al. Prognostic factors for stage III epithelial ovarian cancer : a Gynecologic Oncology Group Study. J Clin Oncol 2007 ; 25 : 3621-7.
6) Gerestein CG, et al. Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer : a systematic review. Gynecol Oncol 2009 ; 114 : 523-7.
7) Thrall MM, et al. Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly. Obstet Gynecol 2011 ; 118 : 537-47.
8) Patankar S, et al. Risk stratification and outcomes of women undergoing surgery for ovarian cancer. Gynecol Oncol 2015 ; 138 : 62-9.
9) Pignata S, et al. Ovarian cancer in the elderly. Crit Rev Oncol Hematol 2004 ; 49 : 77-86.
10) Nordin AJ, et al. Do elderly cancer patients care about cure? Attitudes to radical gynecologic oncology surgery in the elderly. Gynecol Oncol 2001 ; 81 : 447-55.
11) Nurgalieva Z, et al. Risk of hospitalizations associated with adverse effects of chemotherapy in a large community-based cohort of elderly women with ovarian cancer. Int J Gynecol Cancer 2009 ; 19 : 1314-21.
12) Fairfield KM, et al. Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer. J Clin Oncol 2011 ; 29 : 3921-6.
13) Tew WP. Ovarian cancer in the older woman. J Geriatr Oncol 2016 ; 7 : 354-61.
14) Uyar D, et al. Treatment patterns by decade of life in elderly women ( > or=70 years of age) with ovarian cancer. Gynecol Oncol 2005 ; 98 : 403-8.
15) 日本老年医学会. フレイルに関する日本老年医学会からのステートメント. https://www.jpn-geriat-soc.or.jp/info/topics/pdf/20140513_01_01.pdf
17) Bandeen-Roche K, et al. Phenotype of frailty : characterization in the women's health and aging studies. J Gerontol A Biol Sci Med Sci 2006 ; 61 : 262-6.
18) Rolfson DB, et al. Validity and reliability of the Edmonton Frail Scale. Age Ageing 2006 ; 35 : 526-9.
19) Obeid NM, et al. Predictors of critical care-related complications in colectomy patients using the National Surgical Quality Improvement Program : exploring frailty and aggressive laparoscopic approaches. J Trauma Acute Care Surg 2012 ; 72 : 878-83.
20) Uppal S, et al. Frailty index predicts severe complications in gynecologic oncology patients. Gynecol Oncol 2015 ; 137 : 98-101.
21) Barber EL, et al. A preoperative personalized risk assessment calculator for elderly ovarian cancer patients undergoing primary cytoreductive surgery. Gynecol Oncol 2015 ; 139 : 401-6.
22) Freyer G, et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma : a GINECO study. Ann Oncol 2005 ; 16 : 1795-800.
23) Falandry C, et al. Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer related with first-line carboplatin : a GINECO prospective trial. Ann Oncol 2013 ; 24 : 2808-13.
24) Mohile SG, et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy : ASCO Guideline for Geriatric Oncology. J Clin Oncol 2018 ; 36 : 2326-47.
25) Orme JG, et al. Factorial and discriminant validity of the Center for Epidemiological Studies Depression (CES-D) scale. J Clin Psychol 1986 ; 42 : 28-33.
P.332 掲載の参考文献
1) 五十嵐尚子ほか. データでみる日本の緩和ケアの現状. 志真泰夫ほか編. ホスピス緩和ケア白書 2019. ホスピス緩和ケアにおける看護-教育・制度の現状と展望を中心に. 東京 : 青海社 ; 2019.
2) 厚生労働省HPがん対策推進基本計画の概要 (第3期). https://www.mhlw.go.jp/file/04-Houdouhappyou-10901000-Kenkoukyoku-Soumuka/0000196967.pdf
3) 日本産科婦人科学会婦人科腫瘍委員会悪性腫瘍オンライン登録 治療年報. http://plaza.umin.ac.jp/?jsog-go/new5.html
4) Futagami M, et al. Palliative care for patients with gynecologic cancer in Japan : a Japan Society of Gynecologic Palliative Medicine (JSGPM) survey. Asian Pac J Cancer Prev 2016 ; 17 : 4637-42.
5) 斎藤清二ほか訳. ナラティブ・メディスン-物語能力が医療を変える. 東京 : 医学書院 ; 2011. (Charon R. Narrative Medicine : Honoring the Stories of Illness)
6) 藤村正樹. 緩和ケア-婦人科病棟における緩和ケアの実際. 特集 婦人科がん治療周辺領域の進歩. 産婦人科の世界 2006 ; 58 : 1127-33.
7) 藤村正樹. 7. 婦人科がんで遭遇する消化管狭窄, 閉塞. がん患者支援とがんサバイバーのQOL. 産と婦 2013 ; 80 : 205-10.
8) 藤村正樹. 婦人科がん患者の緩和ケアとその個別化に向かって. ゲノム時代の婦人科がん診療を展望する-がんの個性に応じたpersonalizationへの道. 臨床婦人科産科 2015 ; 69 : 34-9.
9) 志真泰夫. 第61回日本婦人科腫瘍学会学術講演会「婦人科腫瘍の緩和医療を考える会」合同企画基調講演. JSGPM Letter 2019 ; 6 : 6.
P.336 掲載の参考文献
1) Klapheke AK, et al. Depressive symptoms and health-related quality of life in older women with gynecologic cancers. J Geriatr Oncol 2019 Oct 25. pii : S1879-4068 (19) 30292-9.
2) Gotze H, et al. Psychological distress of cancer patients with children under 18 years and their partners : a longitudinal study of family relationships using dyadic data analysis. Support Care Cancer 2017 ; 25 : 255-64.
3) Sato I, et al. Prevalence and initial prescription of psychotropics in patients with common cancers in Japan, based on a nationwide health insurance claims database. Psychooncology 2018 ; 27 : 450-7.
4) Massie M, Holland J. Overview of normal reactions and prevalence of psychiatric disorders. In : Holland J, Rowland J, eds. Handbook of Psychooncology. New York : Oxford University Press ; 1989. p.273-82.
5) Lederberg M. The family of the cancer patient. In : Holland JC, et al, editors. Psycho-Oncology. Oxford University Press ; 1998. p.981-93.
6) Lehman DR, et al. Social support for the bereaved : recipients' and providers' perspectives on what is helpful. J Consult Clin Psychol 1986 ; 54 : 438-46
7) Ishida M, et al. Communication disparity between the bereaved and others : what hurts them and what is unhelpful? A nationwide study of the cancer bereaved. J Pain Symptom Manage 2018 ; 55 : 1061-7. e1.
P.340 掲載の参考文献
Mullan F. Seasons of survival : reflections of a physician with cancer. N Engl J Med 1985 ; 313 : 270-3. doi : 10.1056/NEJM198507253130421
Miller KD原書編集, 勝俣範之監訳. がんサバイバー 医学・心理・社会的アプローチでがん治療を結いなおす. 東京 : 医学書院 ; 2012.

最近チェックした商品履歴

Loading...